SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest
Event Reported): June 13, 1999
MAXXIM MEDICAL, INC.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
TEXAS 0-18208 76-0291634
- ---------------------------- ----------- -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
10300 49th Street North
CLEARWATER, FLORIDA 33762
- -------------------------------------------- ---------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 727-561-2100
<PAGE>
ITEM 5. OTHER EVENTS.
MERGER WITH FOX PAINE MEDIC ACQUISITION CORPORATION
On June 13, 1999, the Company entered into an Agreement and Plan of Merger
(the "Merger Agreement") with Fox Paine Medic Acquisition Corporation, a newly
formed Texas corporation ("FPMAC"), pursuant to which investment funds managed
by Fox Paine & Company, LLC, together with members of the Company's senior
executive management and certain other shareholders (collectively, the "Rollover
Shareholders"), will acquire the Company in a recapitalization transaction. In
connection with the acquisition, the existing debt of the Company will be
refinanced, with the Company making a consent solicitation and tender offer for
all of its outstanding 10 1/2% Senior Subordinated Notes, due 2006.
Under the Merger Agreement, FPMAC will be merged with and into the Company
with the Company continuing as the surviving corporation (the "Merger").
Pursuant to the Merger, each outstanding share of the Company's common stock
(except for certain shares held by the Rollover Shareholders, and those
dissenting stockholders who exercise and perfect their appraisal rights) will be
converted into the right to receive a cash payment of $26.00, without interest.
Shares of FPMAC will be converted into shares of stock of the surviving
corporation.
The Company's Board of Directors has unanimously approved the Merger
Agreement and the transactions contemplated thereby, including the Merger. The
proposed transactions are subject to certain conditions, including shareholder
approval, regulatory approvals, the availability of funding under the existing
equity and debt financing commitments, and other customary closing conditions.
Portions of the transactions will be funded in accordance with equity and debt
commitments from investment funds managed by Fox Paine & Company, LLC, and the
balance of the financing necessary to complete the transactions will be funded
in accordance with debt commitments from The Chase Manhattan Bank. The
commitments are subject to customary closing conditions.
The Rollover Shareholders, who will continue as shareholders of the
Company, have entered into voting agreements with FPMAC (the "Voting
Agreements") pursuant to which they have agreed to vote all of their shares,
representing approximately 8.0% of the Company's outstanding common stock, in
favor of the Merger. The Company will call a special meeting of its shareholders
as soon as practicable to consider the approval of the Merger Agreement and the
Merger.
The foregoing summary of the Merger Agreement and the transactions
contemplated thereby is qualified in its entirety by reference to the Merger
Agreement which is attached hereto as Exhibit 2.1 and is incorporated herein by
reference. The press release issued by the Company and Fox Paine in connection
with the execution of the Merger Agreement is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
In connection with its approval of the Merger Agreement, the Board of
Directors of the Company amended the Rights Agreement, dated as of July 10,
1997, by and between the Company and Harris Trust and Savings Bank, as Rights
Agent, to provide that, among other
<PAGE>
things, the approval, execution, delivery and performance of the Merger
Agreement and the Voting Agreements, and the announcement of the same, would not
give rise to a triggering event or distribution date under the Rights Agreement.
The foregoing summary of the Amendment to the Rights Agreement is qualified in
its entirety by reference to the Amendment which is attached hereto as Exhibit
4.1 and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) FINANCIAL STATEMENTS OF BUSINESSES ACQUIRED.
None.
(b) PRO FORMA FINANCIAL INFORMATION.
None.
(c) EXHIBITS.
EXHIBIT
NUMBER EXHIBIT DESCRIPTION
--------- ---------------------
2.1 Agreement and Plan of Merger, dated as of June 13, 1999, between
the Company and Fox Paine Medic Acquisition Corporation.
4.1 Amendment No. 1 to Rights Agreement, dated as of June 13, 1999.
99.1 Press Release, dated June 14, 1999.
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned thereunto duly authorized.
MAXXIM MEDICAL, INC.
By: /s/ ALAN S. BLAZEI
------------------
Alan S. Blazei
Executive Vice President, Treasurer
and Controller(Principal Accounting Officer)
Dated: June 15, 1999
<PAGE>
EXHIBIT INDEX
EXHIBIT
NUMBER EXHIBIT DESCRIPTION
------- -------------------
2.1 Agreement and Plan of Merger, dated as of June 13, 1999, between
the Company and Fox Paine Medic Acquisition Corporation.
4.1 Amendment No. 1 to Rights Agreement, dated as of June 13, 1999.
99.1 Press Release of the Registrant dated June 14, 1999.
EXHIBIT 2.1
================================================================================
AGREEMENT AND PLAN OF MERGER
Dated as of June 13, 1999,
Between
FOX PAINE MEDIC ACQUISITION CORPORATION
And
MAXXIM MEDICAL, INC.
================================================================================
<PAGE>
<TABLE>
<CAPTION>
TABLE OF CONTENTS
PAGE
----
<S> <C> <C>
ARTICLE I THE MERGER, ITS EFFECTS ON THE CAPITAL STOCK OF THE CONSTITUENT
CORPORATIONS, AND THE DEBT OFFER................................... 2
Section 1.1. The Merger......................................................... 2
Section 1.2. Effective Time .................................................... 2
Section 1.3. Effects of the Merger.............................................. 2
Section 1.4. Articles of Incorporation and Bylaws............................... 3
Section 1.5. Directors ......................................................... 3
Section 1.6. Officers .......................................................... 3
Section 1.7. Subsequent Actions ................................................ 3
Section 1.8. Effect of the Capital Stock........................................ 3
Section 1.9. Dissenting Shares ................................................. 5
Section 1.10. List of Stock Options; Cancellation of Stock Options .............. 5
Section 1.11. Payment for Shares................................................. 6
Section 1.12. The Senior Notes Offer and Solicitation............................ 8
Section 1.13. Company Action .................................................... 9
ARTICLE II ASSET DROPDOWN..................................................... 10
Section 2.1. Asset Dropdown .................................................... 10
Section 2.2. Non-Assignment Under Certain Circumstances......................... 11
ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY...................... 11
Section 3.1. Organization and Qualification; Subsidiaries....................... 11
Section 3.2. Capitalization of the Company and its Subsidiaries................. 12
Section 3.3. Authority Relative to this Agreement; Consents and Approvals....... 14
Section 3.4. SEC Reports; Financial Statements.................................. 15
Section 3.5. Debt Offer Documents; Proxy Statement; Form S-4.................... 15
Section 3.6. Consents and Approvals, No Violations.............................. 16
Section 3.7. No Default ........................................................ 17
Section 3.8. No Undisclosed Liabilities; Absence of Changes..................... 17
Section 3.9. Litigation ........................................................ 17
Section 3.10. Compliance with Applicable Law..................................... 17
Section 3.11. Employee Benefit Matters........................................... 18
Section 3.12. Environmental Laws and Regulations................................. 20
Section 3.13. Rights Agreement; State Takeover Statute Inapplicable.............. 21
Section 3.14. Brokers............................................................ 22
Section 3.15. Absence of Certain Changes......................................... 22
Section 3.16. Taxes ............................................................. 22
Section 3.17. Intellectual Property.............................................. 24
Section 3.18. Labor Matters ..................................................... 24
Section 3.19. Opinions of Financial Advisors..................................... 25
Section 3.20. Titles to Properties; Encumbrances................................. 25
Section 3.21. Material Contracts ................................................ 26
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C>
Section 3.22. Product Liability ................................................. 28
Section 3.23. Suppliers and Customers............................................ 29
Section 3.24. Title and Condition of Properties.................................. 29
Section 3.25. Information in Financing Documents................................. 30
Section 3.26. Year 2000 Compliance .............................................. 30
ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER........................ 30
Section 4.1. Organization ...................................................... 30
Section 4.2. Authority Relative to this Agreement............................... 30
Section 4.3. Consents and Approvals; No Violations.............................. 31
Section 4.4. Proxy Statement; Offer Documents................................... 31
Section 4.5. Financing.......................................................... 32
Section 4.6. Brokers............................................................ 32
ARTICLE V COVENANTS.......................................................... 32
Section 5.1. Shareholders Meeting .............................................. 32
Section 5.2 Proxy Statement ................................................... 32
Section 5.3. Conduct of Business of the Company................................. 33
Section 5.4. No Solicitation ................................................... 36
Section 5.5. Access to Information.............................................. 38
Section 5.6. Additional Agreements, Reasonable Efforts.......................... 39
Section 5.7. Public Announcements............................................... 41
Section 5.8. Indemnification ................................................... 41
Section 5.9. Recapitalization .................................................. 42
Section 5.10. Financial Statements............................................... 42
Section 5.11. Certain Agreements with Management................................. 42
ARTICLE VI CONDITIONS TO CONSUMMATION OF THE MERGER........................... 42
Section 6.1. Conditions to the Merger........................................... 42
Section 6.2. Conditions to Each Party's Obligations to Effect the Merger........ 45
ARTICLE VII TERMINATION; AMENDMENT; WAIVER..................................... 45
Section 7.1. Termination ....................................................... 45
Section 7.2. Effect of Termination.............................................. 46
Section 7.3. Fees and Expenses ................................................. 46
Section 7.4. Amendment.......................................................... 47
Section 7.5. Waiver............................................................. 48
ARTICLE VIII MISCELLANEOUS...................................................... 48
Section 8.1. Nonsurvival of Representations and Warranties...................... 48
Section 8.2. Entire Agreement; Assignment....................................... 48
Section 8.3. Validity .......................................................... 48
Section 8.4. Notices............................................................ 48
Section 8.5. Governing Law ..................................................... 49
Section 8.6. Descriptive Headings............................................... 50
Section 8.7. Parties in Interest ............................................... 50
Section 8.8. Counterparts ...................................................... 50
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
<S> <C> <C>
ANNEX A Terms and Conditions to the Debt Offer
EXHIBIT A-1 Equity Commitment Letter to Purchaser
EXHIBIT A-2 Equity Commitment Letter to Circon Buyer
EXHIBIT B Holdco Commitment Letter
EXHIBIT C OpCo Financing Commitment Letters
SCHEDULES Schedules 1.8(b) and 1.10(c)
Company Disclosure Letter
</TABLE>
<PAGE>
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT AND PLAN OF MERGER, dated as of June 13, 1999 (this
"AGREEMENT"), is made by and between Fox Paine Medic Acquisition Corporation, a
Texas corporation ("PURCHASER"), and Maxxim Medical, Inc., a Texas corporation
(the "COMPANY").
WHEREAS, the respective Boards of Directors of the Company and
Purchaser have determined that the merger of Purchaser with and into the Company
(the "MERGER"), upon the terms and subject to the conditions set forth in this
Agreement, would be fair to and in the best interests of their respective
shareholders, and such Boards of Directors have approved such Merger, pursuant
to which each share of common stock, par value $.001 per share (together with
the associated Preferred Share Purchase Rights (the "RIGHTS") issued pursuant to
the Rights Agreement, dated as of July 10, 1997 (the "RIGHTS AGREEMENT"), by and
between the Company and Harris Trust and Savings Bank as rights agent, the
"COMPANY COMMON STOCK"), issued and outstanding immediately prior to the
Effective Time (as defined in Section 1.2) will (except for shares of Company
Common Stock owned, directly or indirectly by the Company or Purchaser, except
for those shares owned by the Specified Shareholders (as defined herein) which
are to be retained pursuant to Section 1.8(b) hereof, and except for any shares
of Common Stock as to which dissenters rights are exercised and perfected
pursuant to applicable law) be converted into the right to receive $26.00 in
cash (the "PER SHARE AMOUNT");
WHEREAS, the Merger and this Agreement require the vote of a
majority of the shares of the Company Common Stock for the approval thereof (the
"COMPANY SHAREHOLDER APPROVAL");
WHEREAS, Purchaser is a newly formed corporation formed by Fox Paine
Capital Fund, L.P. and certain related parties;
WHEREAS, as a condition and inducement to Purchaser's willingness to
enter into this Agreement and consummate the transactions contemplated hereby,
Purchaser has required each of Kenneth W. Davidson, Peter M. Graham, David L.
Lamont, Henry T. DeHart, Jack F. Cahill, Alan S. Blazei, Joseph D. Dailey,
Suzanne R. Garon, Ernest J. Henley, and Davis C. Henley (collectively, the
"SPECIFIED SHAREHOLDERS"), all but one of which is a member of the Company's
senior management or a member of Company's Board of Directors, to enter into a
voting agreement, dated even herewith (the "VOTING AGREEMENT"), pursuant to
which, among other things, each Specified Shareholder agrees to vote all shares
of Company Common Stock beneficially owned by him or her (including without
limitation shares of Company Common Stock issued upon conversion of options of
the Company beneficially owned by the Specified Shareholder) in favor of the
Merger;
WHEREAS, Purchaser and the Company desire to make certain
representations, warranties, covenants and agreements in connection with the
Merger and also to prescribe various conditions to the Merger; and
WHEREAS, the parties hereto intend that the Merger be treated as a
recapitalization for financial reporting purposes.
[SIGNATURE PAGE TO MERGER AGREEMENT]
<PAGE>
NOW, THEREFORE, in consideration of the representations, warranties,
covenants and agreements contained in this Agreement, the parties agree as
follows:
ARTICLE I
THE MERGER, ITS EFFECTS ON THE CAPITAL STOCK
OF THE CONSTITUENT CORPORATIONS, AND THE DEBT OFFER
SECTION 1.1. THE MERGER. Subject to the conditions of this Agreement
and in accordance with the Business Corporation Act of the State of Texas (the
"TBCA"), the Company and Purchaser shall consummate a merger (the "MERGER")
pursuant to which (i) Purchaser shall merge with and into the Company and the
separate corporate existence of Purchaser shall thereupon cease, (ii) the
Company shall be the successor or the surviving corporation in the Merger
(sometimes hereinafter referred to as the "SURVIVING CORPORATION") and shall
continue to be governed by the laws of the State of Texas, and (iii) the
corporate existence of the Company, with all of its rights, privileges,
immunities, powers and franchises, shall continue unaffected by the Merger.
Purchaser may, upon notice to the Company, modify the structure of the Merger if
Purchaser determines it advisable to do so because of tax or other
considerations, and the Company shall promptly enter into any amendment to this
Agreement necessary or desirable to accomplish such structure modification,
PROVIDED that no such amendment shall reduce the Per Share Amount or materially
delay the Closing (as defined below) and, PROVIDED, FURTHER, that in the event
of any such modification of structure, for purposes of determining whether the
condition set forth in Section 6.1(b)(i) has been satisfied, the accuracy of the
Company's representations and warranties shall be determined (unless the Company
otherwise reasonably agrees) as if such modification had not been made.
SECTION 1.2. EFFECTIVE TIME. As soon as practicable after the
satisfaction or waiver of the conditions set forth in Article VI, the parties
hereto shall cause (i) articles of merger (the "ARTICLES OF MERGER") to be
executed and filed on the Closing Date (or on such other date as Purchaser and
the Company may agree) with the Secretary of State of the State of Texas in such
form as required by, and executed in accordance with the relevant provisions of
the TBCA, and (ii) all other filings or recordings required by the TBCA in
connection with the Merger. A closing for the Merger (the "CLOSING") will be
held at the offices of Wachtell, Lipton, Rosen & Katz, counsel to Purchaser, at
10:00 a.m. New York City time (or such other place as the parties may agree) on
second business day after satisfaction or waiver of the conditions set forth in
Article VI (other than those that are to be satisfied on the Closing Date) (the
"CLOSING DATE"). The Merger shall become effective at such time as a Certificate
of Merger is duly issued by the Secretary of State of the State of Texas (the
time the Merger becomes effective being referred to herein as the "EFFECTIVE
TIME").
SECTION 1.3. EFFECTS OF THE MERGER. At the Effective Time, the
Merger shall have the effects as set forth in the applicable provisions of the
TBCA. Without limiting the generality of the foregoing, and subject thereto, at
the Effective Time, all the properties, rights, privileges, powers and
franchises of the Company and Purchaser shall vest in the Surviving Corporation,
and all debts, liabilities and duties of the Company and Purchaser shall become
the debts, liabilities and duties of the Surviving Corporation.
-2-
<PAGE>
SECTION 1.4. ARTICLES OF INCORPORATION AND BYLAWS.
(a) The articles of incorporation of the Company in effect
immediately prior to the Effective Time shall be the articles of incorporation
of the Surviving Corporation until amended in accordance with its terms and
applicable law.
(b) The bylaws of Purchaser in effect immediately prior to
the Effective Time shall be the bylaws of the Surviving Corporation until
amended in accordance with its terms and applicable law.
SECTION 1.5. DIRECTORS. The directors of Purchaser immediately prior
to the Effective Time shall be the initial directors of the Surviving
Corporation, each to hold office in accordance with the articles of
incorporation and bylaws of the Surviving Corporation until such director's
successor is duly elected or appointed and qualified.
SECTION 1.6. OFFICERS. The officers of the Company immediately prior
to the Effective Time shall be the initial officers of the Surviving
Corporation, each to hold office in accordance with the articles of
incorporation and bylaws of the Surviving Corporation until such officer's
successor is duly elected or appointed and qualified.
SECTION 1.7. SUBSEQUENT ACTIONS. If at any time after the Effective
Time the Surviving Corporation shall consider or be advised that any deeds,
bills of sale, assignments, assurances or any other actions or things are
necessary or desirable to vest, perfect or confirm of record or otherwise in the
Surviving Corporation its right, title or interest in, to or under any of the
rights, properties or assets of either of the Company or Purchaser acquired or
to be acquired by the Surviving Corporation as a result of, or in connection
with the Merger or otherwise to carry out this Agreement, the officers and
directors of the Surviving Corporation shall be authorized to execute and
deliver, in the name and on behalf of either the Company or Purchaser, all such
deeds, bills of sale, assignments and assurances and to take and do, in the name
and on behalf of each of such corporations or otherwise, all such other actions
and things as may be necessary or desirable to vest, perfect or confirm any and
all right, title and interest in, to and under such rights, properties or assets
in the Surviving Corporation or otherwise to carry out this Agreement.
SECTION 1.8. EFFECT OF THE CAPITAL STOCK. As of the Effective Time,
by virtue of the Merger and without any action on the part of the Company,
Purchaser or any holder of any shares of Company Common Stock ("SHARES") or any
shares of capital stock of Purchaser:
(a) Each share of common stock of Purchaser issued and
outstanding immediately prior to the Effective Time shall be converted into one
share of the common stock, par value $.001 per share, of the Company following
the Merger.
(b) Each issued and outstanding share of Company Common
Stock held by the Specified Shareholders immediately prior to the Effective
Time, other than as set forth in Schedule 1.8(b) hereto, shall not be canceled
as provided below but be retained by such holder and remain outstanding and
unaffected by the Merger.
(c) Each share of Company Common Stock that is owned by or
held in the treasury of the Company or owned by any subsidiary of the Company
immediately prior to the
-3-
<PAGE>
Effective Time, shall automatically be canceled and retired and shall cease to
exist, and no cash, Company Common Stock or other consideration shall be
delivered or deliverable in exchange therefor.
(d) Shares of Company Common Stock issued and outstanding
immediately prior to the Effective Time (other than (i) any shares to be issued
pursuant to Section 1.8(a), (ii) any shares to remain outstanding pursuant to
Section 1.8(b), (iii) any shares to be canceled pursuant to Section 1.8(c) and
(iv) any Dissenting Shares (as defined below)), together with the Associated
Rights, held by each shareholder of the Company shall be converted into the
right to receive (i) an amount in cash (the "MERGER CONSIDERATION") equal to the
product of (A) the number of such shares of Company Common Stock owned by such
shareholder prior to the Effective Time, and (B) the Per Share Amount. The
Merger Consideration shall be payable to the holder of shares of Company Common
Stock, without interest thereon, upon the surrender of the certificate or
certificates formerly representing such Shares in the manner provided in Section
5.2 and less any required withholding of taxes. From and after the Effective
Time, all such Shares so converted into the Merger Consideration shall no longer
be outstanding and shall be deemed to be canceled and retired and shall cease to
exist, and each holder of a certificate or certificates formerly representing
any such Shares shall cease to have any rights with respect thereto, except the
right to receive the Merger Consideration therefor upon the surrender of such
certificate or certificates in accordance with Section 1.11, or the right, if
any, to receive payment from the Surviving Corporation in accordance with
Articles 5.11, 5.12 and 5.13 of the TBCA. Anything contained herein to the
contrary notwithstanding, with respect to any Person (as defined in Section 2.2)
(other than any Specified Shareholder) who has purchased shares of Company
Common Stock pursuant to the terms of the Company's Senior Management Stock
Purchase Plan and who as of the Effective Time has an amount outstanding and
unpaid under a promissory note(s) entered into between such Person and the
Company under such plan, the Company shall withhold from the aggregate Merger
Consideration payable to any such Person in respect of shares of Company Common
Stock canceled in the Merger (subject to obtaining any required consent of any
such Person) the amount necessary to satisfy the outstanding obligation under
the promissory note(s) in full (including the amount equal to any imputed
interest if such Person authorized the Company to do so).
SECTION 1.9. DISSENTING SHARES. Anything in this Agreement to the
contrary notwithstanding, shares of Company Common Stock which are issued and
outstanding immediately prior to the Effective Time and which are held by
shareholders who have the right to dissent with respect to the Merger pursuant
to Article 5.11 of the TBCA ("DISSENTING SHARES") shall not be converted into or
be exchangeable for the right to receive the Merger Consideration, but the
holders of such Dissenting Shares shall be entitled to receive payment of the
fair value of such Dissenting Shares in accordance with the provisions of the
TBCA, unless and until such holders shall have failed to perfect or shall have
effectively withdrawn or lost such right under the TBCA. If any such holder
shall have failed to perfect or shall have effectively withdrawn or lost such
right, such holder's shares of Company Common Stock shall thereupon be converted
into and become exchangeable only for the right to receive, as of the Effective
Time, the Merger Consideration without any interest thereon. The Company shall
give Purchaser (i) prompt notice of any written demands received by the Company
for payment of fair value in respect of any shares of Company Common Stock,
attempted written withdrawals of such demands, and any other instruments served
pursuant to the TBCA and received by the Company relating to share-
-4-
<PAGE>
holders' rights to dissent with respect to the Merger and (ii) the opportunity
to direct all negotiations and proceedings with respect to any exercise of such
rights under the TBCA. The Company shall not, except with the prior written
consent of Purchaser, voluntarily make any payment with respect to any demands
for payment of fair value for capital stock of the Company, offer to settle or
settle any such demands or approve any withdrawal of any such demands.
SECTION 1.10. LIST OF STOCK OPTIONS; CANCELLATION OF STOCK OPTIONS.
(a) The Company has heretofore provided Purchaser a true and
complete list (the "STOCK OPTION LIST") of each option to purchase shares of
Company Common Stock (the "STOCK OPTIONS") granted under each employee and
director stock option plan or arrangement (the "COMPANY STOCK PLANS")
outstanding as of the date hereof (along with the exercise prices thereof). The
Company represents and warrants that as of the date hereof, other than as
previously disclosed in the Stock Option List, no outstanding Stock Options are
held by any Specified Shareholder. Stock Options held by any Specified
Shareholder and any other person permitted by Purchaser in writing after the
date hereof to participate in the option rollover (collectively, the "ROLLOVER
PARTICIPANTS") are referred to as "ROLLOVER OPTIONS".
(b) The term "OPTION CANCELLATION TIME" shall mean the time
that is immediately prior to the Effective Time.
(c) At the Option Cancellation Time, 448,336 Rollover
Options (as specified in Schedule 1.10(c) (the "Canceled Rollover Options"))
shall be canceled, and shall be of no further force or effect.
(d) At the Option Cancellation Time, each then outstanding
Stock Option (whether vested or unvested), other than any Canceled Rollover
Option, shall be canceled and, in consideration of such cancellation, the
Company shall pay to the holder in full satisfaction of such Stock Option,
subject to any applicable withholding tax, an amount in cash equal to the
product of (i) the excess, if any, of the Per Share Amount over the exercise
price per share of Company Common Stock of such Stock Option and (ii) the number
of shares of Company Common Stock subject to such Stock Option.
(e) The Company (i) shall take all actions necessary,
including seeking written consents from each holder (other than the Rollover
Participants), to cause the actions and effects specified in Section 1.10 to
occur, and (ii) shall take all actions necessary to provide that, effective as
of the Option Cancellation Time, (A) except as necessary in connection with the
treatment of Rollover Options, each of the Company Stock Plans shall be
terminated and no new options shall be granted thereunder, (B) the provisions in
any other plan, program or arrangement providing for the issuance or grant of
any other interest in respect of the capital stock of the Company or any of its
subsidiaries shall be amended to provide that no new issuances or grants may be
made thereunder, and (C) no holder of Stock Options will have any right to
receive any shares of capital stock of the Company or, if applicable, the
Surviving Corporation, upon exercise of any Stock Option.
-5-
<PAGE>
SECTION 1.11. PAYMENT FOR SHARES.
(a) Prior to the Effective Time, Purchaser shall designate a
bank or trust company reasonably acceptable to the Company to act as paying
agent in connection with the Merger (the "PAYING AGENT") pursuant to a paying
agent agreement providing for the matters set forth in this Section 1.11 and
otherwise reasonably satisfactory to the Company. At the Effective Time, the
Company shall deposit, or cause to be deposited, in trust with the Paying Agent
for the benefit of holders of shares of Company Common Stock, the aggregate
consideration to which such holders shall be entitled at the Effective Time
pursuant to Section 1.8(d). Such funds shall be invested as directed by the
Company or the Surviving Corporation pending payment thereof by the Paying Agent
to holders of the shares of Company Common Stock. Earnings from such investments
shall be the sole and exclusive property of the Company and the Surviving
Corporation and no part thereof shall accrue to the benefit of the holders of
the shares of Company Common Stock.
(b) Promptly after the Effective Time, the Paying Agent
shall mail to each record holder, as of the Effective Time, of an outstanding
certificate or certificates which immediately prior to the Effective Time
represented outstanding shares of Company Common Stock (the "CERTIFICATES"),
whose shares were converted pursuant to Section 1.8(d) into the right to receive
the Merger Consideration (i) a letter of transmittal (which shall specify that
delivery shall be effected, and risk of loss and title to the Certificates shall
pass, only upon proper delivery of the Certificates to the Paying Agent and
shall be in such form and have such other provisions not inconsistent with this
Agreement as Purchaser may specify) and (ii) instructions for use in effecting
the surrender of the Certificates in exchange for payment of the Merger
Consideration (together, the "TRANSMITTAL DOCUMENTS"). Upon surrender of a
Certificate or Certificates for cancellation to the Paying Agent or to such
other agent or agents as may be appointed by Purchaser, together with such
letter of transmittal, duly executed, the holder of such Certificate or
Certificates shall be entitled to receive in exchange therefor (as promptly as
practicable) the Merger Consideration in respect of all shares of Company Common
Stock formerly represented by such Certificate or Certificates, without any
interest thereon, pursuant to Section 1.8(d) The Certificate(s) so surrendered
shall forthwith be canceled. If payment of the Merger Consideration is to be
made to a Person other than the Person in whose name the surrendered Certificate
or Certificates are registered, it shall be a condition of payment that the
Certificate(s) so surrendered shall be properly endorsed or shall otherwise be
in proper form for transfer, that the signatures on the Certificate(s) or any
related stock power shall be properly guaranteed and that the Person requesting
such payment shall have paid any transfer and other taxes required by reason of
the payment of the Merger Consideration to a Person other than the registered
holder of the Certificate(s) surrendered or shall have established to the
satisfaction of the Surviving Corporation that such tax either has been paid or
is not applicable. Until surrendered in accordance with the provisions of and as
contemplated by this Section 1.11, any Certificate (other than Certificates
representing shares of Company Common Stock subject to Sections 1.8(a), (b) and
(c) and other than Dissenting Shares) shall be deemed at any time after the
Effective Time to represent only the right to receive the Merger Consideration
in cash without interest as contemplated by this Section 1.11. Upon the
surrender of Certificates in accordance with the terms and instructions
contained in the Transmittal Documents, the Company shall cause the Paying Agent
to pay the holder of such Certificates in exchange therefor cash in an amount
equal to the Merger Consid-
-6-
<PAGE>
eration (other than Certificates representing Dissenting Shares and Certificates
representing shares of Company Common Stock subject to Sections 1.8(a), (b) and
(c)).
(c) At the Effective Time, the stock transfer books of the
Company shall be closed and there shall not be any further registration of
transfers of any shares of capital stock thereafter on the records of the
Company. If, after the Effective Time, Certificates (other than Dissenting
Shares or those subject to Sections 1.8(a), (b) and (c)) are presented to the
Surviving Corporation, they shall be canceled and exchanged for the
consideration provided for, and in accordance with the procedures set forth, in
this Section 1.11. No interest shall accrue or be paid on any cash payable upon
the surrender of a Certificate or Certificates which immediately before the
Effective Time represented outstanding shares of Company Common Stock.
(d) From and after the Effective Time, the holders of
Certificates evidencing ownership of shares of Company Common Stock outstanding
immediately prior to the Effective Time (other than those subject to Section
1.8(b)) shall cease to have any rights with respect to such shares of Company
Common Stock except as otherwise provided herein or by applicable law.
(e) If any Certificate shall have been lost, stolen or
destroyed, upon the making of an affidavit of that fact by the Person claiming
such Certificate to be lost, stolen or destroyed, the Surviving Corporation
shall pay or cause to be paid in exchange for such lost, stolen or destroyed
Certificate the relevant portion of the Merger Consideration in accordance with
Section 1.8(d) for shares of Company Common Stock represented thereby. When
authorizing such payment of any portion of the Merger Consideration in exchange
therefor, the board of directors of the Surviving Corporation may, in its
discretion and as a condition precedent to the payment thereof, require the
owner of such lost, stolen or destroyed Certificate to give the Surviving
Corporation a bond in such sum as it may direct as indemnity against any claim
that may be made against the Surviving Corporation with respect to the
Certificate alleged to have been lost, stolen or destroyed.
(f) Promptly following the date which is one year after the
Effective Time, the Surviving Corporation shall be entitled to require the
Paying Agent to deliver to it any cash (including any interest received with
respect thereto), Certificates and other documents in its possession relating to
the Merger, which had been made available to the Paying Agent and which have not
been disbursed to holders of Certificates, and thereafter such holders shall be
entitled to look to the Surviving Corporation (subject to abandoned property,
escheat or similar laws) only as general creditors thereof with respect to any
portion of the Merger Consideration payable upon due surrender of their
Certificates, without any interest thereon.
(g) The Merger Consideration paid in the Merger shall be net
to the holder of shares of Company Common Stock in cash, subject to reduction
only for any applicable Federal withholding taxes or, as set forth in Section
1.11(b), stock transfer taxes payable by such holder.
(h) Anything to the contrary in this Section 1.11
notwithstanding, none of the Paying Agent, Purchaser or the Surviving
Corporation shall be liable to any holder of a Certificate formerly representing
Shares for any amount properly delivered to a public official pursuant to any
applicable abandoned property, escheat or similar law. If Certificates are not
surrendered
-7-
<PAGE>
prior to two years after the Effective Time, unclaimed funds payable with
respect to such Certificates shall, to the extent permitted by applicable law,
become the property of the Surviving Corporation, free and clear of all claims
or interest of any Person previously entitled thereto.
SECTION 1.12. THE SENIOR NOTES OFFER AND SOLICITATION.
(a) Provided that this Agreement shall not have been
terminated in accordance with Section 7.1 and none of the events set forth in
Annex A shall have occurred or be existing, the Company shall promptly after the
date of this Agreement, but in no event later than five business days from the
date a request is made by the Purchaser (which request shall not be made prior
to the sixth business day following the date of this Agreement), commence an
offer to purchase all of the outstanding aggregate principal amount of the
Company's 10-1/2% Senior Subordinated Senior Notes (the "SENIOR NOTES") issued
pursuant to that certain Indenture, dated as of July 30, 1996, among the
Company, certain of its subsidiaries, and First Union National Bank of North
Carolina, as Trustee (the "SENIOR NOTES INDENTURE"), on the terms and conditions
set forth in and attached as Annex A hereto, and such other customary terms and
conditions as are reasonably acceptable to Purchaser (the "DEBT OFFER"). Without
limiting the foregoing, the Debt Offer (and the provisions of Annex A hereto),
shall include the solicitation of consents to amendments to the terms of the
Senior Notes and the Senior Notes Indenture that shall be reasonably
satisfactory to Purchaser and shall include, without limitation, the elimination
of the negative covenants contained therein and the elimination of any
restrictions applicable to the transactions contemplated by this Agreement or
any of the financing contemplated thereby (the "SENIOR NOTES AMENDMENTS"). The
Company shall waive any of the conditions to the Debt Offer and make any other
changes in the terms and conditions of the Debt Offer as reasonably requested by
Purchaser, and the Company shall not, without Purchaser's prior written consent,
waive any condition to the Debt Offer, make any changes to the terms and
conditions of the Debt Offer set forth in Annex A or make any other changes in
the terms and conditions of the Debt Offer. The Company covenants and agrees
that, subject to the terms and conditions of this Agreement, including, but not
limited to, Annex A, it will accept for payment and thereafter pay for, as
promptly as practicable after expiration of the Debt Offer, Senior Notes and
consents concurrently with the consummation of the Merger.
(b) Subject to Section 7.1, the Company shall, from time to
time at the direction of Purchaser, extend the Debt Offer.
(c) Promptly following the date of this Agreement, the
Company shall prepare an offer to purchase the Senior Notes and forms of the
related letter of transmittal (collectively, the "DEBT OFFER TO PURCHASE") and
summary advertisement, as well as all other information and exhibits
(collectively, the "DEBT OFFER DOCUMENTS"). Purchaser and the Company will
cooperate with each other in the preparation of the Debt Offer Documents. All
mailings to the holders of Senior Notes in connection with the Debt Offer shall
be subject to the prior review, comment and approval of Purchaser. The Company
will use its reasonable efforts to cause the Debt Offer Documents to be mailed
to the holders of the Senior Notes within five business days from the date a
request is made by Purchaser (which request shall not be made prior to the sixth
business day following the date of this Agreement). The Debt Offer Documents
will comply in all material respects with the provisions of applicable state and
federal laws. Each of Purchaser and the Company agrees promptly to correct any
information provided by it for use in the Debt Offer
-8-
<PAGE>
Documents if and to the extent that it shall have become false or misleading in
any material respect, and the Company further agrees to take all steps necessary
to cause the Debt Offer Documents as so corrected to be disseminated to holders
of Senior Notes as and to the extent required by applicable state and federal
laws.
SECTION 1.13. COMPANY ACTION.
(a) The Company hereby approves of and agrees to undertake
the Debt Offer and represents and warrants that the Board of Directors of the
Company (the "COMPANY BOARD"), at a meeting duly called and held, has, subject
to the terms and conditions set forth herein, (i) determined that this
Agreement, which provides, among other things, for the Debt Offer, the Circon
Sale (as defined in Section 5.6(d)) and the Merger, is advisable, fair to, and
in the best interests of, the shareholders of the Company, (ii) resolved to
recommend approval and adoption of the plan of merger (within the meaning of
Article 5.03 of the TBCA) contained in this Agreement by such shareholders of
the Company, (iii) approved the Merger and all of the other Transactions, for
purposes of Article 13.03 of the TBCA and taken all necessary steps to render
Article 13.03 of the TBCA inapplicable to the Transactions contemplated hereby,
(iv) resolved to elect, to the extent permitted by law, not to be subject to any
state takeover law other than Article 13.03 of the TBCA that may purport to be
applicable to the Transactions contemplated hereby, (v) has taken all action
under the Rights Agreement to make the representations and warranties contained
in Section 3.13 true and correct in all respects, and (vi) resolved to
recommend, and recommended, that the shareholders of the Company approve and
adopt this Agreement and the Merger. The determinations, resolutions and
recommendations referred to in the immediately preceding sentence are
collectively referred to herein as the "COMPANY BOARD RECOMMENDATION". The
Company shall include a statement of such recommendation and approval in the
Proxy Statement (as defined in Section 3.5). The Company further represents that
Lazard Freres & Co. LLC (the "FINANCIAL ADVISOR") has delivered to the Board its
written opinion that, as of the date of such opinion, the Per Share Amount to be
received in the Merger by the holders of Shares (other than Purchaser and the
Specified Shareholders) is fair from a financial point of view to such holders.
The Company agrees to, and has been authorized by the Financial Advisor to,
permit the inclusion of the fairness opinion (or a reference thereto) in the
Proxy Statement.
(b) The Company shall take all action as may be necessary to
effect the Debt Offer as contemplated by this Agreement, including, without
limitation, promptly mailing the Debt Offer Documents to the record holders and
beneficial owners of the Senior Notes.
ARTICLE II
ASSET DROPDOWN
Section 2.1. ASSET DROPDOWN. If requested by Purchaser in order to
facilitate the financing contemplated hereby, the Company shall organize, or
cause to be organized under the laws of the State of Delaware a corporation
("COMPANY SUB") and thereafter maintain its good standing under the laws of the
State of Delaware and qualify it to do business in such jurisdictions as may be
necessary to comply with the terms of Section 3.1. Purchaser shall be afforded
the opportunity to review and approve all documents prepared in connection with
the formation of Company Sub.
-9-
<PAGE>
In accordance with the first sentence of this Section 2.1, as so requested,
immediately before or concurrent with the Effective Time, subject to
satisfaction or waiver of all conditions to the Merger, the Company shall sell,
convey, assign, transfer and deliver to Company Sub, and the Company shall cause
Company Sub to acquire from the Company, all of the rights, title and interests
of the Company in and to all of the assets, properties, operations and
businesses and all other rights and privileges of every nature, kind and
description, whether tangible or intangible (including goodwill), whether
accrued, contingent or otherwise, of the Company as such assets, properties,
operations, businesses, rights and privileges may exist on the date and time of
the transfer (collectively, the "COMPANY ASSETS"); PROVIDED, HOWEVER, that the
Company shall retain sufficient cash or cash equivalents in order to finance the
consummation of the Merger. The transfer of the Company Assets contemplated by
this Section 2.1 shall be effected by appropriate bills of sale and other
evidences of transfer or assignment, all in forms reasonably satisfactory to the
Company and Purchaser. Simultaneously therewith, the Company shall assign to
Company Sub, and shall cause Company Sub to assume and agree to pay, perform and
be liable and responsible for, any and all of its liabilities, obligations,
debts whatsoever of the business of the Company, whether mature or unmatured,
liquidated or unliquidated, fixed or contingent, including as the "Company"
under Section 5.2 of the Senior Notes Indenture ("LIABILITIES"). The assumption
of Liabilities by Company Sub pursuant to this Section 2.1 shall be evidenced by
an assumption agreement or other comparable document in form and substance
reasonably satisfactory to the Company and Purchaser.
Section 2.2. NON-ASSIGNMENT UNDER CERTAIN CIRCUMSTANCES. Anything
contained in this Agreement to the contrary notwithstanding, this Agreement
shall not constitute an agreement to sell, convey, assign, transfer or deliver
("TRANSFER") any interest in any instruments, commitments, contracts, leases,
permits or other agreements or arrangements or any claim, right or benefit, or
any Liability arising thereunder or resulting therefrom ("INSTRUMENTS"), if such
a Transfer or an attempt to make such a Transfer without authorization,
approval, consent or waiver of a third person ("AUTHORIZATIONS") would
constitute a breach or violation thereof or affect adversely the rights of
Company Sub or the Company thereunder; and any transfer hereunder of such
Instruments that requires Authorizations shall be made subject to such
Authorizations being obtained. In the event that any such Authorizations are not
obtained on or prior to the Effective Time, the Company shall use commercially
reasonable efforts to obtain any such Authorization after the Effective Time,
and the Company shall, to the fullest extent permitted by law and any
instruments (including by acting as an agent of Company Sub), hold such
instruments in trust for the exclusive use and benefit of Company Sub such that
Company Sub receives the interest of the Company in the benefits therefrom until
such time as such Authorizations are obtained. "PERSON" or "PERSON" means and
includes natural persons, corporations, limited partnerships, limited liability
companies, general partnerships, joint stock companies, joint ventures,
associations, companies, trusts, banks, trust companies, land trusts, business
trusts or other organizations, whether or not legal entities, and all
Governmental Entities.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company hereby represents and warrants to Purchaser as follows:
-10-
<PAGE>
Section 3.1. ORGANIZATION AND QUALIFICATION; SUBSIDIARIES.
(a) Each of the Company and its Subsidiaries is a
corporation duly organized, validly existing and in good standing under the laws
of the jurisdiction of its incorporation and has all requisite corporate or
other power and authority and all necessary governmental approvals to own, lease
and operate its properties and to carry on its businesses as now being
conducted, except where the failure to be in good standing or to have such
power, authority and governmental approvals, would not, individually or in the
aggregate, have a Company Material Adverse Effect. The Company has heretofore
delivered to Purchaser accurate and complete copies of the articles of
incorporation and bylaws, as currently in effect, of the Company and accurate
and complete copies of the certificate or articles of incorporation and bylaws
(or other governing document), as currently in effect, of each of its
Subsidiaries. As used in this Agreement, the term "SUBSIDIARY" shall mean, with
respect to any party, any corporation or other organization, whether
incorporated or unincorporated or domestic or foreign to the United States of
which (i) such Person or any other Subsidiary of such Person is a general
partner (excluding such partnerships where such Person or any Subsidiary of such
Person do not have a majority of the voting interest in such partnership) or
(ii) at least a majority of the securities or other interests having by their
terms ordinary voting power to elect a majority of the board of directors or
others performing similar functions with respect to such corporation or other
organization is directly or indirectly owned or controlled by such Person or by
any one or more of its Subsidiaries, or by such Person and one or more of its
Subsidiaries. The term "COMPANY MATERIAL ADVERSE EFFECT" means any event,
change, circumstance or effect that is or could reasonably be expected to be
materially adverse to (a) the business, results of operations, condition
(financial or otherwise), assets or liabilities of the Company and its
Subsidiaries, taken as a whole, or (b) the ability of the Company to consummate
any of the transactions contemplated by this Agreement, including the Debt
Offer, the Circon Sale and the Merger (collectively, the "Transactions"). The
schedule of disclosures delivered by the Company to Purchaser together with the
execution of this Agreement (the "COMPANY DISCLOSURE SCHEDULE") sets forth in
Section 3.1(a) a complete list of the Company's Subsidiaries.
(b) Each of the Company and its Subsidiaries is duly
qualified or licensed and in good standing to do business in each jurisdiction
in which the property owned, leased or operated by it or the nature of the
business conducted by it makes such qualification or licensing necessary, except
in such jurisdictions where the failure to be so duly qualified or licensed and
in good standing would not, individually or in aggregate, have a Company
Material Adverse Effect.
(c) Except as set forth in Section 3.1(c) of the Company
Disclosure Schedule, the Company does not own any equity or similar interest in
any Person.
Section 3.2. CAPITALIZATION OF THE COMPANY AND ITS SUBSIDIARIES.
(a) The authorized capital stock of the Company consists of:
40,000,000 shares of Company Common Stock and 20,000,000 shares of preferred
stock, par value $1.00 per share (the "PREFERRED STOCK"). As of June 9, 1999,
14,276,682 shares of Company Common Stock are issued and outstanding, no shares
of the Preferred Stock are outstanding. All of the Shares have been validly
issued, and are fully paid, nonassessable and free of preemptive rights. As of
June 9, 1999, a total of 1,498,920 Shares are reserved for issuance pursuant to
outstanding
-11-
<PAGE>
Stock Options under the Company Stock Plans, and no other Shares are subject to
issuance pursuant to Stock Options. Set forth in Section 3.2(a) of the Company
Disclosure Schedules is a complete and accurate list of the Company Stock Plans
and the number of Shares reserved for issuance pursuant to Stock Options
outstanding as of June 9, 1999 under each such Company Stock Plan, and no other
Shares are subject to issuance pursuant to such Company Stock Plans. Since June
9, 1999, no shares of the Company's capital stock have been issued other than
pursuant to Stock Options set forth on the Stock Option List and, since June 9,
1999, no stock options have been granted. Except as set forth above and except
for the Rights to, among other things, purchase Series A Participating Preferred
Stock issued pursuant to the Rights Agreement, there are outstanding (i) no
shares of capital stock or other voting securities of the Company, (ii) no
securities of the Company or any of its Subsidiaries convertible into or
exchangeable for shares of capital stock or voting securities of the Company,
(iii) no options or other rights to acquire from the Company or any of its
Subsidiaries, and no obligations of the Company or any of its Subsidiaries to
issue, any capital stock, voting securities or securities convertible into or
exchangeable for capital stock or voting securities of the Company, and (iv) no
equity equivalents, interests in the ownership or earnings of the Company or any
of its Subsidiaries or other similar rights (collectively, "COMPANY
SECURITIES"). There are no outstanding obligations of the Company or any of its
Subsidiaries to repurchase, redeem or otherwise acquire any Company Securities.
(b) Except as set forth in Section 3.2(b) of the Company
Disclosure Schedule, all of the outstanding, capital stock of, or other
ownership interests in, each Subsidiary of the Company, is owned by the Company,
directly or indirectly, free and clear of any Lien or any other limitation or
restriction (including any restriction on the right to vote or sell the same,
except as may be provided as a matter of law). All such shares have been validly
issued, fully paid and nonassessable, and have been issued free of preemptive
rights. There are no securities of the Company or any of its Subsidiaries
convertible into or exchangeable for, no options or other rights to acquire from
the Company or any of its Subsidiaries, and no other contract, understanding,
arrangement or obligation (whether or not contingent) providing for the issuance
or sale, directly or indirectly, of any capital stock or other ownership
interests in, or any other securities of, any Subsidiary of the Company. There
are no contractual obligations of the Company or any of its Subsidiaries to
repurchase, redeem or otherwise acquire any outstanding shares of capital stock
or other ownership interests in any Subsidiary of the Company. For purposes of
this Agreement, "LIEN" means, with respect to any asset (including, without
limitation, any security) any option, claim, mortgage, lien, pledge, charge,
security interest or encumbrance or restrictions of any kind in respect of such
asset.
(c) The Shares and the Rights constitute the only class of
equity securities of the Company or any of its Subsidiaries registered or
required to be registered under the Exchange Act.
(d) Other than the Voting Agreements, there are no voting
trusts or other agreements or understandings to which the Company or any of its
Subsidiaries is a party with respect to the voting of the capital stock of the
Company or any of the Subsidiaries.
(e) Other than the Outstanding Indebtedness, there is no
outstanding Indebtedness of the Company or any of its Subsidiaries. Except as
identified in Section 3.2(e) of the
-12-
<PAGE>
Company Disclosure Schedule, no such Indebtedness of the Company or its
Subsidiaries contains any restriction upon (i) the prepayment of such
Indebtedness, (ii) the incurrence of Indebtedness by the Company or its
Subsidiaries, respectively, or (iii) the ability of the Company or its
Subsidiaries to grant any Liens on its properties or assets.
(f) For purposes of this Agreement, "INDEBTEDNESS" shall
include (i) all indebtedness for borrowed money or for the deferred purchase
price of property or services (other than current trade liabilities incurred in
the ordinary course of business and payable in accordance with customary
practices, and excluding ordinary operating leases), (ii) any other indebtedness
which is evidenced by a note, bond, debenture or similar instrument, (iii) all
obligations under conditional sale or other title retention agreements relating
to property purchased, (iv) capital lease or sale-leaseback obligations, (v) all
liabilities secured by any Lien on any property (other than ordinary operating
leases), and (vi) any guarantee or assumption of any of the foregoing in clauses
(i) through (v) or guaranty of minimum equity or capital or any make-whole or
similar obligation. The term "OUTSTANDING INDEBTEDNESS" means (a) the Senior
Notes, (b) Indebtedness not in excess of $265,000,000 as of the date hereof
under that certain Third Amended and Restated Credit Agreement, dated as of
January 4, 1999 (the "CREDIT AGREEMENT"), by and among the Company, NationsBank,
N.A., as Agent, The Bank of Nova Scotia and First Union Bank, as managing
agents, and certain other banks named therein, and (c) capitalized leases
outstanding on the date hereof not in excess of $10,500,000 in the aggregate.
The aggregate principal amount of the outstanding Senior Notes does not exceed
$100,000,000, and there is no accrued but unpaid interest thereon other than
interest accruing since the last regular interest payment date.
Section 3.3. AUTHORITY RELATIVE TO THIS AGREEMENT; CONSENTS AND
APPROVALS.
(a) The Company has all the necessary corporate power and
authority to execute and deliver this Agreement and to consummate the
Transactions in accordance with the terms hereof (subject to obtaining the
necessary approval and adoption of this Agreement and the Merger by the
shareholders of the Company). The execution, delivery and performance of this
Agreement by the Company and the consummation by it of the Transactions have
been duly and validly authorized by the Board and, except for obtaining the
approval of the Company's shareholders in connection with the Merger as
contemplated by Section 5.1 hereof, no other corporate action or corporate
proceedings on the part of the Company is necessary to authorize the execution
and delivery by the Company of this Agreement and the consummation by it of the
Transactions. This Agreement has been duly and validly executed and delivered by
the Company and, assuming due and valid authorization, execution and delivery by
Purchaser, constitutes a valid, legal and binding agreement of the Company,
enforceable against the Company in accordance with its terms.
(b) The Board has duly and validly approved, and taken all
corporate actions required to be taken by the Board for the consummation of, the
Transactions, including, without limitation, all actions required to ensure that
the representations and warranties set forth in Section 3.13 are, and shall
remain, true and correct in all respects.
(c) No approval of the shareholders of the Company is
required (by the Company's articles of incorporation or bylaws, or by applicable
law) with respect to the entering into
-13-
<PAGE>
of this Agreement or the consummation of any of the Transactions other than the
approval of the Merger by holders of a majority of the outstanding shares of
Company Common Stock.
Section 3.4. SEC REPORTS; FINANCIAL STATEMENTS.
(a) Since January 1, 1996, the Company has filed with the
SEC all forms, reports, schedules, statements and other documents required to be
filed by it with the SEC pursuant to the Securities Act of 1933, as amended (the
"SECURITIES ACT"), and the SEC's rules and regulations promulgated thereunder,
and the Securities Exchange Act of 1934, as amended (the "EXCHANGE ACT"), and
the SEC's rules and regulations promulgated thereunder (any such documents filed
since January 1, 1996 and prior to the date hereof being collectively, the
"COMPANY SEC DOCUMENTS"). The Company SEC Documents, including without
limitation, any financial statements or schedules included therein, at the time
filed, or in the case of registration statements on their respective effective
dates, (i) complied in all material respects with the applicable requirements of
the Exchange Act and the Securities Act, as the case may be, and the rules and
regulations promulgated thereunder and (ii) did not at the time filed (or, in
the case of registration statements, at the time of effectiveness), contain any
untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements made therein, in
light of the circumstances under which they were made, not misleading. No
Subsidiary of the Company is required to file any form, report or other document
with the SEC. The financial statements included in the Company SEC Documents
(the "FINANCIAL STATEMENTS") (i) have been prepared from, and are in accordance
with, the books and records of the Company and its Subsidiaries, (ii) complied
in all material respects with applicable accounting requirements and with the
published rules and regulations of the SEC with respect thereto, (iii) have been
prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (except as
may be indicated in the notes thereto) ("GAAP") and (iv) fairly present in all
material respects the consolidated financial position and the consolidated
results of operations and cash flows (and changes in financial position, if any)
of the Company and its Subsidiaries as of the times and for the periods referred
to therein, except that any such Financial Statements that are unaudited,
interim financial statements were or are subject to normal and recurring year
end adjustments.
(b) The Company has heretofore made available to Purchaser,
in the form filed with the SEC (including any amendments thereto), (i) its
Annual Reports on Form 10-K for each of its three most recently completed fiscal
years, (ii) all definitive proxy statements relating to the Company's meetings
of shareholders (whether annual or special) held since January 1, 1996 and (iii)
all other reports (other than Quarterly Reports on Form 10-Q) or registration
statements filed by the Company with the SEC since January 1, 1996.
Section 3.5. DEBT OFFER DOCUMENTS; PROXY STATEMENT; FORM S-4. None
of the information included in (i) the Debt Offer Documents, shall, at the time
the Debt Offer Documents or any amendments or supplements thereto are first
published, sent or given to holders of the Senior Notes contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading, (ii) the
registration statement on Form S-4 to be filed, if necessary, with the
Securities and Exchange Commission (the "SEC") by the Company in connection with
any issuance of Company Common Stock in connection with the
-14-
<PAGE>
Merger (such Form S-4, as amended or supplemented, is herein referred to as the
"FORM S-4") will, at the time the Form S-4 is filed with the SEC, and at any
time it is amended or supplemented or at the time it becomes effective under the
Securities Act, contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the
statements therein not misleading and (iii) the proxy statement to be sent to
the shareholders of the Company in connection with the Shareholders Meeting (as
defined in Section 5.1) (such proxy statement, as amended or supplemented, is
herein referred to as the "PROXY STATEMENT") will, at the date it is first
mailed to the Company's shareholders or at the time of the Shareholders Meeting,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they are made, not
misleading. If the filing of the Form S-4 is required, the Form S-4 will, as of
its effective date, and the prospectus contained therein will, as of its date,
comply as to form in all material respects with the requirements of the
Securities Act and the rules and regulations promulgated thereunder. The Proxy
Statement will comply as to form in all material respects with the requirements
of the Exchange Act and the rules and regulations promulgated thereunder, except
that no representation is made by the Company with respect to statements made
therein based on information supplied in writing by Purchaser specifically for
inclusion in the Proxy Statement. For purposes of this Agreement, the parties
agree that statements made and information in the Debt Offer Documents, the Form
S-4 (if one is filed) and the Proxy Statement relating to the federal income tax
consequences of the transactions herein contemplated to holders of Company
Common Stock shall be deemed to be supplied by the Company and not by Purchaser.
Section 3.6. CONSENTS AND APPROVALS, NO VIOLATIONS. Except as set
forth in Section 3.6 of the Company Disclosure Schedule, no filing with or
notice to, and no permit, authorization, consent or approval of, any federal,
state, local or foreign court or tribunal or administrative, governmental or
regulatory body, agency or authority (a "GOVERNMENTAL ENTITY"), is required on
the part of the Company or any of its Subsidiaries for the execution, delivery
and performance by the Company of this Agreement or the consummation by the
Company of the Transactions, except (i) in connection with the applicable
requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended (the "HSR ACT"), (ii) pursuant to the applicable requirements of the
Securities Act and the Exchange Act and the SEC's rules and regulations
promulgated thereunder, (iii) the filing and if applicable, recordation of the
Articles of Merger pursuant to the TBCA, (iv) such filings as are or may become
necessary or desirable in connection with the organization and capitalization of
Company Sub, or (v) where the failure to obtain such permits, authorizations,
consents or approvals or to make such filings or give such notice would not have
a Company Material Adverse Effect. Neither the execution, delivery and
performance of this Agreement by the Company nor the consummation by the Company
of the Transactions will (A) conflict with or result in any breach of any
provision of the respective articles of incorporation or bylaws (or similar
governing documents) of the Company or of any its Subsidiaries, (B) except as
set forth in Section 3.6 of the Company Disclosure Schedule, result in a
violation or breach of, or constitute (with or without due notice or lapse of
time or both) a default (or give rise to any right of termination, amendment,
cancellation or acceleration) under, any of the terms, conditions or provisions
of any note, bond, mortgage, indenture, lease, license, contract, agreement or
other instrument or obligation to which the Company or any of its Subsidiaries
is a party or by which any of them or any of their respective properties or
assets may be bound, other than breaches or defaults under the Credit Agreement
upon consummation of the
-15-
<PAGE>
Debt Offer without repayment thereof, or (C) violate any order, writ,
injunction, decree, law, statute, rule or regulation applicable to the Company
or any of its Subsidiaries or any of their respective properties or assets,
except in the case of (B) or (C) for violations, breaches or defaults which
would not, individually or in the aggregate, have a Company Material Adverse
Effect.
Section 3.7. NO DEFAULT. None of the Company or any of its
Subsidiaries is in default or violation (and no event has occurred which with
notice or the lapse of time or both would constitute a default or violation) of
any term, condition or provision of (i) its articles of incorporation or bylaws
(or similar governing documents), (ii) any note, bond, mortgage, indenture,
lease, license, contract, agreement or other instrument or obligation to which
the Company or any of its Subsidiaries is now a party or by which any of them or
any of their respective properties or assets may be bound or (iii) any order,
writ, injunction, decree, law, statute, rule or regulation applicable to the
Company, any of its Subsidiaries or any of their respective properties or
assets, except in the case of (ii) or (iii) for violations, breaches or defaults
that would not, individually or in the aggregate, have a Company Material
Adverse Effect.
Section 3.8. NO UNDISCLOSED LIABILITIES; ABSENCE OF CHANGES. Except
(i) for liabilities incurred pursuant to the terms of the Agreement, or (ii) as
set forth in the Company SEC Documents filed since November 1, 1998, neither the
Company nor any of its Subsidiaries has, or has incurred since November 1, 1998,
any liabilities or obligations of any nature, whether or not accrued, contingent
or otherwise, that have a Company Material Adverse Effect or, other than in the
ordinary course of business and consistent with past practices, that would be
required in accordance with GAAP to be reflected or reserved against on a
consolidated balance sheet, or in the notes thereto, of the Company and its
Subsidiaries prepared in accordance with GAAP.
Section 3.9. LITIGATION. Except as disclosed in the Company SEC
Documents or in Section 3.9 of the Company Disclosure Schedule, there is no
suit, claim, action, proceeding or investigation pending or, to the knowledge of
the Company, threatened against, affecting or involving the Company or any of
its Subsidiaries or any of their respective properties or assets before any
Governmental Entity with respect to which there is a reasonable likelihood of an
adverse determination which would have a Company Material Adverse Effect. Except
as disclosed in the Company SEC Documents or in Section 3.9 of the Company
Disclosure Schedule, neither the Company nor any of its Subsidiaries is subject
to any outstanding order, writ, injunction or decree which has a Company
Material Adverse Effect.
Section 3.10. COMPLIANCE WITH APPLICABLE LAW. Except as set forth in
Section 3.10 of the Company Disclosure Schedule, the Company and its
Subsidiaries hold all permits, licenses, variances, exemptions, orders and
approvals of all Governmental Entities (including under applicable regulations
adopted by the U.S. Food and Drug Administration and the U.S. Food, Drug and
Cosmetic Act) necessary for it to own, lease or operate its properties and
assets and to carry on its business as now conducted ("COMPANY PERMITS") except
where the failure to hold such permits, licenses, variances, exemptions, orders
and approvals would not, individually or in the aggregate, have a Company
Material Adverse Effect. There has not occurred any material default under, or
violation of, or failure of compliance under, any such Company Permit. Except as
set forth in Section 3.10 of the Company Disclosure Schedule, the businesses of
the Company and its Subsidiaries are not being, and have not been, conducted in
violation of any law, ordinance or regulation of any Governmental Entity
(including under applicable regulations adopted
-16-
<PAGE>
by the U.S. Food and Drug Administration and the U.S. Food, Drug and Cosmetic
Act) except for violations or possible violations which individually or in the
aggregate will not have a Company Material Adverse Effect. Except as set forth
in Section 3.10 of the Company Disclosure Schedule, no investigation or review
by any Governmental Entity (including under applicable regulations adopted by
the U.S. Food and Drug Administration and the U.S. Food, Drug and Cosmetic Act)
with respect to the Company or any of its Subsidiaries or any of their
respective products is, or during the past three years has been, pending or, to
the knowledge of the Company, threatened nor, to the knowledge of the Company,
has any Governmental Entity indicated an intention to conduct the same. This
Section 3.10 shall not be applicable to compliance with Environmental Laws (on
permits required thereunder), which is the subject of Section 3.12.
Section 3.11. EMPLOYEE BENEFIT MATTERS.
(a) All employee or director benefit plans, arrangements or
agreements, whether or not written, including without limitation any employee
welfare benefit plan within the meaning of Section 3(1) of the Employee
Retirement Income Security Act of 1974, as amended ("ERISA"), any employee
pension benefit plan within the meaning of Section 3(2) of ERISA (whether or not
such plan is subject to ERISA) and any bonus, incentive, deferred compensation,
vacation, stock purchase, stock option, severance, employment, change of control
or fringe benefit plan, program or agreement that is or has since January 1,
1994 (or prior to such date if such plan, program or arrangement could result in
any liability of the Company or any Subsidiary after the date of this Agreement)
been sponsored, maintained or contributed to for the benefit of any current or
former employee or director of the Company or any Subsidiary are listed in
Section 3.11(a) of the Company Disclosure Schedule (the "COMPANY BENEFIT
PLANS"). True and complete copies of (i) the Company Benefit Plans (or, in the
case of any unwritten Company Benefit Plan, a description thereof) and any
amendment thereto, (ii) the most recent summary plan description (or similar
document) for each Company Benefit Plan, (iii) the three most recent Annual
Reports (Form 5500 Series) and accompanying schedules, if any, and (iv) the most
recent determination letter from the IRS (if applicable) for such Company
Benefit Plan have been made available to the Purchaser.
(b) Except as set forth in Section 3.11(b) of the Company
Disclosure Schedule, (i) each Company Benefit Plan has been maintained and
administered in all material respects in compliance with its terms and with all
applicable laws including, but not limited to, ERISA, and the Internal Revenue
Code of 1986, as amended (the "CODE"); (ii) each Company Benefit Plan intended
to be qualified under Section 401(a) of the Code has been determined by the
Internal Revenue Service (the "IRS") to be so qualified (or such qualification
is pending, or such plan is maintained under a prototype plan approved by the
IRS), and, to the knowledge of the Company, no event has occurred that could
reasonably be expected to adversely affect the qualified status of such Company
Benefit Plan; (iii) neither the Company nor any of its Subsidiaries has incurred
or is reasonably likely to incur any liability or penalty under Sections 4975 or
4976 of the Code or Sections 409 or 502(i) of ERISA; (iv) there are no pending,
nor has the Company or any of its Subsidiaries received notice of any
threatened, claims against or otherwise involving any of the Company Benefit
Plans (other than routine claims for benefits); (v) no Company Benefit Plan is
under audit or investigation by the IRS, the Department of Labor or the Pension
Benefit Guaranty Corporation, and to the knowledge of the Company, no such audit
or investigation is pending or threatened; (vi) all contributions or other
payments required to be made as of
-17-
<PAGE>
the date of this Agreement to or pursuant to the Company Benefit Plans have been
made or accrued for in the Company's Financial Statements; (vii) neither the
Company nor any entity under "common control" with the Company within the
meaning of Sections 414(b), (c), (m) or (o) of the Code or Section 4001 of ERISA
("ERISA Affiliate") has at any time contributed to, or been required to
contribute to, any "pension plan" (as defined in Section 3(2) of ERISA) that is
subject to Title IV of ERISA or Section 412 of the Code, including without
limitation, any "multi-employer plan" (as defined in Sections 3(37) and
4001(a)(3) of ERISA) (a "Multiemployer Plan"); (viii) no Company Benefit Plan is
subject to the laws of any jurisdiction other than the United States; (ix)
neither the Company nor any of its Subsidiaries has any obligation for retiree
health or life benefits; (x) the Company or its Subsidiaries may amend or
terminate any of the Company Benefit Plans without incurring any liability
thereunder; (xi) all amounts of deferred compensation benefits under any Company
Benefit Plan have been properly accrued on the Financial Statements of the
Company and its Subsidiaries to the extent required under GAAP; and (xii) each
Company Benefit Plan which is an "employee welfare benefit plan" within the
meaning of Section 3(1) of ERISA is either insured pursuant to a contract of
insurance whereby the insurance company bears any risk of loss with respect to
such claims or covered under a contract with a health maintenance organization
(an "HMO") pursuant to which the HMO bears the liability for such claims.
(c) Except as set forth in Section 3.11(c) of the Company
Disclosure Schedule, the consummation of the Transactions will not (either alone
or upon the occurrence of any additional or subsequent events) (i) constitute an
event under any Company Benefit Plan, trust, or loan that will or may result in
any payment (whether of severance pay or otherwise), acceleration, forgiveness
of indebtedness, vesting, distribution, increase in benefits or obligation to
fund benefits with respect to any current or former employee, officer or
director of the Company or any Subsidiary, or (ii) result in the triggering or
imposition of any restrictions or limitations on the right of the Company or the
Purchaser to amend or terminate any Company Benefit Plan and receive the full
amount of any excess assets remaining or resulting from such amendment or
termination, subject to applicable taxes. Except as set forth in Section 3.11(c)
of the Company Disclosure Schedule, no payment or benefit which will or may be
made by the Company, any of its Subsidiaries, the Purchaser or any of their
respective affiliates with respect to any employee, officer or director of the
Company or its Subsidiaries will be characterized as an "excess parachute
payment," within the meaning of Section 280G(b)(1) of the Code, and no amount of
any such payment or benefit will fail to be deductible by the Company by reason
of Section 162(m) of the Code.
(d) Except as set forth in Section 3.11(d) of the Company
Disclosure Schedule, with respect to each Company Benefit Plan that is subject
to Title IV or Section 302 of ERISA or Section 412 or 4971 of the Code: (i)
there does not exist any accumulated funding deficiency within the meaning of
Section 412 of the Code or Section 302 of ERISA, whether or not waived; (ii) the
fair market value of the assets of each such Company Benefit Plan equals or
exceeds the actuarial present value of all accrued benefits under such Plan
(whether or not vested), based upon the actuarial assumptions used to prepare
the most recent actuarial report for such Plan; (iii) no reportable event within
the meaning of Section 4043(c) of ERISA for which the 30-day notice requirement
has not been waived has occurred, and the consummation of the transactions
contemplated by this agreement will not result in the occurrence of any such
reportable event; (iv) all premiums to the Pension Benefit Guaranty Corporation
(the "PBGC") have
-18-
<PAGE>
been timely paid in full; (v) no liability (other than for premiums to the PBGC)
under Title IV of ERISA has been or is expected to be incurred by the Company or
its Subsidiaries; and (vi) the PBGC has not instituted proceedings to terminate
any such Company Benefit Plan and, to the Company's and each of its Subsidiary's
knowledge, no condition exists that presents a risk that such proceedings will
be instituted or which would constitute grounds under Section 4042 of ERISA for
the termination of, or the appointment of a trustee to administer, any such
Company Benefit Plan.
(e) None of the Company and its Subsidiaries nor any ERISA
Affiliate has incurred any "withdrawal liability" (as defined in Part I of
Subtitle E of Title IV of ERISA) ("Withdrawal Liability"), as a result of a
complete or partial withdrawal from a Multiemployer Plan, that has not been
satisfied in full. With respect to each Company Benefit Plan that is a
Multiemployer Plan: (i) if the Company or any of its Subsidiaries or any of
their respective ERISA Affiliates were to experience a withdrawal or partial
withdrawal from such plan, no Withdrawal Liability would be incurred that would
have a Company Material Adverse Effect; and (ii) none of the Company and its
Subsidiaries, nor any of their respective ERISA Affiliates has received any
notification, nor has any reason to believe, that any such Company Benefit Plan
is in reorganization, has been terminated, is insolvent, or may reasonably be
expected to be in reorganization, to be insolvent, or to be terminated.
Section 3.12. ENVIRONMENTAL LAWS AND REGULATIONS.
(a) Except as set forth in the Company SEC Documents or
Section 3.12 of the Company Disclosure Schedule, (i) the Company and each of its
Subsidiaries is in compliance with all applicable federal, state, local and
foreign laws and regulations relating to pollution or protection of human health
or the environment (including, without limitation, ambient air, surface water,
ground water, land surface or subsurface strata) or emissions, discharges,
releases, disposal, or handling of any pollutants or toxic or hazardous
substances, wastes or materials (including, without limitation, petroleum, and
petroleum products, asbestos or asbestos containing materials, polychlorinated
biphenyls, radon or lead or lead-based paints or materials (collectively,
"ENVIRONMENTAL LAWS"), except for non-compliance that individually or in the
aggregate would not have a Company Material Adverse Effect, which compliance
includes, but is not limited to, the possession by the Company and its
Subsidiaries of all permits and other governmental authorizations required under
applicable Environmental Laws, and compliance with the terms and conditions
thereof; (ii) neither the Company nor any of its Subsidiaries has received
written (or, to the Company's knowledge, oral) notice of, or, is the subject of,
any material action, cause of action, claim, investigation, demand or notice by
any such Person alleging liability under or non-compliance with any
Environmental Law (an "ENVIRONMENTAL CLAIM") including, without limitation,
relating to any contractor, subcontractor or agent of the Company or for the
business, or relating in any way to any prior facilities, locations, or business
of the Company or any of its Subsidiaries; and (iii) there are no conditions or
circumstances that are reasonably likely to result in any liability of the
Company or any of its Subsidiaries under any Environmental Law, prevent or
interfere with any such compliance thereunder in the future including, without
limitation, relating to any contractor, subcontractor or agent of the Company or
for the business, or relating in any way to any prior facilities, locations, or
business of the Company or any of its Subsidiaries, except for any such
conditions or circumstances that individually or in the aggregate would not have
a Company Material Adverse Effect. There are no permits or other governmental
authori-
-19-
<PAGE>
zations held by the Company or required for the Company's business that are
required to be transferred or reissued, or that are otherwise prohibited from
being transferred or reissued, pursuant to any Environmental Laws as a result of
the transactions contemplated by this Agreement. The Company has provided to
Purchaser all environmental assessments, reports, data, results of
investigations, or compliance or other environmental audits conducted by or for
the Company, or otherwise relating to the Company's or any Subsidiary's business
or properties (owned, leased or operated).
(b) There are no Environmental Claims which individually or
in the aggregate would have a Company Material Adverse Effect that are pending
or, to the knowledge of the Company, threatened against the Company or any of
its Subsidiaries or, to the knowledge of the Company, against any Person whose
liability for any Environmental Claim the Company or any of its Subsidiaries has
or is reasonably likely to have been retained or assumed either contractually or
by operation of law.
Section 3.13. RIGHTS AGREEMENT; STATE TAKEOVER STATUTE INAPPLICABLE.
(a) The Company has taken all necessary action so that none
of the execution of this Agreement or the Voting Agreements, the making of the
Debt Offer, the acquisition of Senior Notes or consents pursuant to the Debt
Offer, or the consummation of the Merger or the Circon Sale or the other
Transactions will (i) cause the Rights issued pursuant to the Rights Agreement
to become exercisable, (ii) cause Purchaser or any of its affiliates to become
an Acquiring Person (as such term is defined in the Rights Agreement) or (iii)
give rise to a Distribution Date or a Triggering Event (as each such term is
defined in the Rights Agreement). The Company has delivered to Purchaser true
and complete copies of all amendments to the Rights Agreement that fulfill the
requirements of this Section 3.13 and such amendments are in full force and
effect.
(b) As of the date hereof and at all times through and
including the Effective Time, Article 13.03 of the TBCA shall be inapplicable to
the Transactions contemplated by this Agreement and all future transactions
between the Company and any of Purchaser and, to the extent the Specified
Shareholders, or any of them, could be deemed to be or become (by virtue of the
Transactions) an "affiliated shareholder" or an "affiliate or associate of the
affiliated shareholder" (as such terms are used in Article 13.03 of the TBCA),
the Specified Shareholders.
Section 3.14. BROKERS. No broker, finder or investment banker (other
than the Financial Advisor, a true and correct copy of whose engagement
agreement has been delivered to Purchaser) is entitled to any brokerage,
finder's or other fee or commission in connection with the Transactions based
upon arrangements made by or on behalf of the Company. The fees to which the
Financial Advisor shall be entitled to in connection with the transactions
contemplated by this Agreement and the portion thereof heretofore paid are set
forth in Section 3.14 of the Company Disclosure Schedule.
Section 3.15. ABSENCE OF CERTAIN CHANGES. Except as set forth in
Section 3.15 of the Company Disclosure Schedule or disclosed in the Company SEC
Documents filed prior to the date hereof, since November 1, 1998, the Company
and each of its Subsidiaries have conducted its businesses only in the ordinary
course of business and consistent with past practice and (a)
-20-
<PAGE>
there has not been any Company Material Adverse Effect and (b) the Company has
not taken any of the actions set forth in paragraphs (a) through (q) of Section
5.3.
Section 3.16. TAXES.
(a) The Company and each of its Subsidiaries on or prior to
the date of this Agreement has filed or has had filed on its behalf, and will
file or will have filed on its behalf prior to the Effective Time, in a timely
manner (within any applicable extension periods) with the appropriate
governmental entity all income and other material Tax Returns (as defined
herein) required to be filed with respect to Taxes (as defined herein) of the
Company and each of its Subsidiaries, and such Tax Returns are correct and
complete in all material respects. The most recent financial statements
contained in the Company SEC Documents provide an adequate accrual for the
payment of Taxes for all periods covered by such financial statements.
(b) All material Taxes with respect to the Company and its
Subsidiaries have been paid in full to the extent required to be so paid or have
been provided for in accordance with GAAP on the Company's most recent balance
sheet (as of the date of such balance sheet) which is part of the Company SEC
Documents.
(c) There are no outstanding agreements or waivers extending
the statutory period of limitations applicable to any federal, state, local or
foreign income or other material Tax Returns required to be filed by or with
respect to the Company and its Subsidiaries.
(d) No deficiency, delinquency or default for any Tax has
been claimed, proposed or assessed against the Company or any of its
Subsidiaries which has not been abated or paid in full, and neither the Company
nor any Subsidiary has received written notice of any such deficiency,
delinquency or default nor does the Company otherwise have knowledge of any
threat of any governmental entity to assert such deficiency, delinquency or
default or any facts or circumstances that would form a basis of such threat. No
audit by any tax authority is pending or, to the Company's knowledge, threatened
with respect to any Tax Returns filed by, or Taxes due from, the Company or any
of its Subsidiaries.
(e) There are no liens for Taxes upon the assets of the
Company or any of its Subsidiaries except statutory liens for current Taxes not
yet due.
(f) No power of attorney has been executed by, or on behalf
of, the Company or any of its Subsidiaries with respect to any matter relating
to Taxes which is currently in force.
(g) Neither the Company nor any of its Subsidiaries is a
party to or bound by or has any obligation under any written or unwritten Tax
sharing, Tax indemnity or similar agreement or arrangement.
(h) There are no outstanding requests for any extension of
time within which to file any Tax Return or within which to pay any Taxes.
(i) Neither the Company nor any of its Subsidiaries has made
an election under Section 341(f) of the Code.
-21-
<PAGE>
(j) Except as set forth in Section 3.16(j) of the Company
Disclosure Schedule, neither the Company nor any of its Subsidiaries has been a
member of an affiliated group filing a consolidated federal income tax return
(other than the affiliated group of which the Company is the common parent) or
has any liability for the Taxes of any person (other than the Company and its
Subsidiaries) under Treasury Regulation Section 1.1502-6 (or any similar
provision of state, local or foreign law).
(k) The Company is not, and during the preceding 5-year
period has not been, a "United States real property holding corporation" within
the meaning of Section 897(c)(2) of the Code.
(l) For purposes of this Agreement, (i) "TAXES" shall mean
all taxes, charges, fees, levies or other assessments, including, without
limitation, income, gross receipts, sales, use, AD VALOREM, goods and services,
capital, transfer, franchise, profits, license, withholding, payroll,
employment, employer health, excise, estimated, severance, stamp, occupation,
property or other taxes, customs duties, fees, assessments or charges of any
kind whatsoever, together with any interest and any penalties, additions to tax
or additional amounts imposed by any taxing authority and (ii) "TAX RETURN"
shall mean any report, return, document, declaration or other information or
filing required to be supplied to any taxing authority or jurisdiction with
respect to Taxes.
Section 3.17. INTELLECTUAL PROPERTY.
(a) Except as set forth on Section 3.17(a) of the Company
Disclosure Schedule, and except for such failures to own or have the right to
use as would not have a Company Material Adverse Effect, the Company owns or has
the right to use all intellectual property rights used in the conduct of its
business, including without limitation all patents and patent applications,
trademarks, trademark registrations and applications, copyrights and copyright
registrations and applications, computer programs, technology, know-how, trade
secrets, proprietary processes and formulae (collectively, the "INTELLECTUAL
PROPERTY"). Other than as would not have a Company Material Adverse Effect, the
Company owns or has the right to use all such Intellectual Property free and
clear of all Liens.
(b) Section 3.17(b) of the Company Disclosure Schedule sets
forth a list of all material license agreements under which the Company or any
of its Subsidiaries has granted or received the right to use any Intellectual
Property, and the Company is not in material default under any such license.
(c) Except as set forth in Section 3.17(c) of the Company
Disclosure Schedule, no Person has a right to receive a royalty or similar
payment in respect of any item of Intellectual Property pursuant to any
contractual arrangements entered into by the Company or otherwise. No former or
present employees, officers or directors of the Company hold any right, title or
interest, directly or indirectly, in whole or in part, in or to any Intellectual
Property.
(d) There are no claims or suits pending or, to the
knowledge of the Company, threatened, and the Company has received no notice of
any claim or suit (i) alleging that the conduct of the Company's business
infringes upon or constitutes the unauthorized use of the proprietary rights of
any third party or (ii) challenging the ownership, use, validity or
enforceability
-22-
<PAGE>
of the Intellectual Property. To the knowledge of the Company, no Intellectual
Property of the Company is being violated or infringed upon by any third party.
Except as set forth in Section 3.17(d) of the Company Disclosure Schedule, there
are no settlements, consents, judgments, orders or other agreements which
restrict the Company's rights to use any Intellectual Property.
Section 3.18. LABOR MATTERS.
(a) (i) There is no labor strike, dispute, slowdown,
stoppage or lockout pending, or, to the knowledge of the Company, threatened
against or affecting the Company or any of its Subsidiaries and during the past
five years from the date of this Agreement there has not been any such action,
(ii) except as set forth in Section 3.18(a) of the Company Disclosure Schedule,
neither the Company nor any of its Subsidiaries is a party to or bound by any
collective bargaining or similar agreement with any labor organization, or work
rules or practices agreed to with any labor organization or employee association
applicable to employees of the Company or any of its Subsidiaries, (iii) except
as set forth in Section 3.18(a) of the Company Disclosure Schedule, none of the
employees of the Company or any of its Subsidiaries is represented by any labor
organization and the Company does not have any knowledge of any union organizing
activities among the employees of the Company or any of its Subsidiaries within
the past five years, and (iv) there are no complaints, lawsuits or other
proceedings pending or, to the knowledge of the Company, threatened in writing
in any forum by or on behalf of any present or former employee of the Company or
any of its Subsidiaries, any applicant for employment or classes of the
foregoing alleging breach by the Company or its Subsidiaries of any express or
implied contract or employment, any laws governing employment or the termination
thereof or other discriminatory, wrongful or tortious conduct in connection with
the employment relationship, which, individually or in the aggregate, could
reasonably be expected to have a Company Material Adverse Effect.
(b) The Company and its Subsidiaries and each member of
their respective business enterprises has complied with the Worker Adjustment
and Retraining Notification Act (the "WARN ACT") and any similar state, local or
foreign law or regulation. There has not occurred a "mass layoff" (as defined in
the WARN Act) affecting any site of employment or facility of the Company or its
Subsidiaries, and none of the Company's or its Subsidiaries' employees has
suffered an "employment loss" (as defined in the WARN Act) during the six month
period prior to the date of this Agreement.
(c) With respect to any collectively bargained agreement to
which the Company or any of its Subsidiaries is a party and that has been
renewed or renegotiated after November 1, 1998, the terms, including the costs
to the Company or its Subsidiaries, of such new or renogiatated agreement are
not less favorable in any material respect to the Company or its Subsidiaries
than the terms of the agreement as in effect prior to any such renewal or
renegotiation.
Section 3.19. OPINIONS OF FINANCIAL ADVISORS. The Financial Advisor
has delivered its written opinion, to the Board to the effect that, as of the
date of such opinion, the Per Share Amount to be received in the Merger by the
holders of Shares (other than Purchaser and the Specified Shareholders) is fair
from a financial point of view to such holders, a copy of which opinion has been
delivered to Purchaser.
-23-
<PAGE>
Section 3.20. TITLES TO PROPERTIES; ENCUMBRANCES. Except for matters
or conditions which, individually or in the aggregate, could not be reasonably
expected to have a Company Material Adverse Effect,
(a) Section 3.20(a) of the Company Disclosure Schedule sets
forth a complete list of all real property (including land, buildings and other
improvements) owned by the Company or its Subsidiaries (the "OWNED REAL
PROPERTY"), such description including, for each parcel of Owned Real Property,
the address thereof, the approximate acreage thereof, and the use thereof. The
Company or its Subsidiaries has good and marketable title to the Owned Real
Property, free and clear of all Liens, other than Permitted Liens (as defined
below). For purposes of this Agreement, "PERMITTED LIENS" means (i) mechanics',
carriers', workers', repairers', materialmen's, warehousemen's, landlords' and
other similar Liens arising in the ordinary course of the Company's business,
(ii) Liens arising or resulting from any action taken by or on behalf of
Purchaser, (iii) Liens for current Taxes not yet due or payable or for
supplemental Taxes for which the Company has not received a written notice of
assessment, and (iv) any other covenants, conditions, restrictions,
reservations, rights, non-monetary Liens, easements, encumbrances, encroachments
and other matters affecting title which could not, individually or in the
aggregate, be reasonably expected to result in a Company Material Adverse
Effect.
(b) The Real Property constitutes, in the aggregate, all of
the real property used to conduct the Business in the manner conducted
subsequent to October 31, 1998. The term "Real Property" means the Owned Real
Property, any property subject to a Real Property Lease (as defined in Section
3.21(a)(viii)), and any property subject to a lease or agreement of that would
have been included within the meaning of the term Real Property Lease if not for
the minimum dollar amounts set forth in Section 3.21(a)(viii).
(c) Except as set forth in Section 3.20(c) of the Company
Disclosure Schedule, each of the Real Properties (i) is in satisfactory
operating condition and repair and is structurally sound, with no material
alterations or repairs being required thereto under applicable law or insurance
company requirements; (ii) consists of sufficient land, parking areas, driveways
and other improvements and lawful means of access and utility service to permit
the use thereof in the manner and for the material purposes to which it is
presently devoted; and (iii) is otherwise suitable and adequate in all material
respects for its current use, operation and occupancy.
(d) There are no pending or, to the Company's knowledge,
threatened proceedings regarding the amount of the Taxes on, or the assessed
valuation of, any Real Property, or relating to eminent domain or the
condemnation of any portion of the Real Property, or impact fees, special
assessments or similar matters with respect thereto.
Section 3.21. MATERIAL CONTRACTS.
(a) Except for contracts filed as exhibits to the Company's
Annual Report on Form 10-K for the year ended November 1, 1998 (the "COMPANY
1998 10-K"), Section 3.21(a) of the Company Disclosure Schedule lists each of
the following contracts and agreements (including, without limitation, oral
agreements) of the Company and each of its Subsidiaries (such contracts and
agreements, together with all contracts and agreements disclosed in Section
3.17(b)
-24-
<PAGE>
of the Company Disclosure Schedule or filed as exhibits to the Company 1998
10-K, being "MATERIAL CONTRACTS"):
(i) each contract, agreement and other arrangement for
the purchase of inventory, spare parts, other materials or
personal property with any supplier or for the furnishing of
services to the Company and each of its Subsidiaries or
otherwise related to the businesses of the Company and each of
its Subsidiaries under the terms of which the Company or any of
its Subsidiaries: (A) are likely to pay or otherwise give
consideration of more than $1,000,000 in the aggregate during
the calendar year ended December 31, 1999 or (B) are likely to
pay or otherwise give consideration of more than $2,000,000 in
the aggregate over the remaining term of such contract;
(ii) each contract, agreement and other arrangement
for the sale of inventory or other property or for the
furnishing of services by the Company or any of its
Subsidiaries which: (A) is likely to involve consideration of
more than $1,000,000 in the aggregate during the calendar year
ended December 31, 1999 or (B) is likely to involve
consideration of more than $2,000,000 in the aggregate over the
remaining term of the contract;
(iii) all material broker, distributor, dealer,
manufacturer's representative, franchise, agency, sales
promotion, market research, marketing, consulting and
advertising contracts and agreements to which the Company or
any of its Subsidiaries is a party;
(iv) all management contracts and contracts with
independent contractors or consultants (or similar
arrangements) to which the Company or any of its Subsidiaries
is a party and which are not cancelable without penalty or
further payment in excess of $200,000 and without more than 30
days' notice;
(v) all contracts and agreements relating to
Indebtedness of the Company or any of its Subsidiaries or to
any direct or indirect guaranty by the Company or any of its
Subsidiaries of Indebtedness of any other Person, other than
any such contracts or agreements as do not involve more than
$50,000 individually or $250,000 in the aggregate;
(vi) all contracts, agreements, commitments, written
understandings or other arrangements with any Governmental
Entity, to which the Company or any of its Subsidiaries is a
party (other than arrangements entered into in the ordinary
course of business with hospitals or other medical facilities
owned or operated by any such Governmental Entity);
(vii) all contracts and agreements containing any
provision or covenant limiting or purporting to limit the
ability of the Company or any of its Subsidiaries to (i) sell
any products or services of or to any other Person, (ii) engage
in any line of business or (iii) compete with or to obtain
products or services from any Person or limiting the ability of
any Person to provide products or services to the Company or
any of its Subsidiaries, in each case in any geographic area or
during any period of time;
-25-
<PAGE>
(viii) all contracts and agreements (each, a "Real
Property Lease") relating to the lease of real property used by
the Company or its Subsidiaries requiring annual payments in
excess of $200,000 or aggregate payments over the remaining
term of the contract or agreement in excess of $1,000,000 ; and
(ix) all other contracts and agreements, whether or
not made in the ordinary course of business, which are material
to the Company and its Subsidiaries, taken as a whole, or the
conduct of the business of the Company and its Subsidiaries,
taken as a whole, or the absence of which would, in the
aggregate, have a Company Material Adverse Effect.
(b) Except as would not have a Company Material Adverse
Effect, each Material Contract: (i) is legal, valid and binding on the Company
or its respective Subsidiary party thereto and, to the knowledge of the Company,
the other parties thereto, and is in full force and effect and (ii) upon
consummation of the Transactions, except to the extent that any consents set
forth in Section 3.6 of the Company Disclosure Schedule are not obtained, shall
continue in full force and effect without penalty or other adverse consequence.
Except as would not have a Company Material Adverse Effect, neither the Company
nor any of its Subsidiaries is in breach of, or default under, any Material
Contract. As of the date hereof, neither the Company nor any Subsidiary has
received any written or, to the Company's knowledge, oral notice of a material
default (which has not been cured), offset or counterclaim under any Material
Contract, or any other written or, to the Company's knowledge, oral
communication calling upon it to comply with any provision of any Contract or
asserting noncompliance therewith or asserting the Company or any subsidiary has
waived or altered its rights thereunder, nor has the Company or any Subsidiary
received any written or, to the Company's knowledge, oral notice that any party
to any Material Contract intends or is threatening to terminate or fail to
exercise any renewal or extension of any Material Contract.
(c) No other party to any Material Contract is, to the
knowledge of the Company, in material breach thereof or default thereunder.
(d) There is no contract, agreement or other arrangement
granting any Person any preferential right to purchase any of the properties or
assets of the Company or any of its Subsidiaries, other than inventory in the
ordinary course of business consistent with past practice.
Section 3.22. PRODUCT LIABILITY.
(a) Except as set forth in Section 3.22 of the Company
Disclosure Schedule, (i) there is no notice, demand, claim, action, suit
inquiry, hearing, proceeding, notice of violation or investigation of a civil,
criminal or administrative nature by or before any Governmental Entity pending
against or involving the Company or any of its Subsidiaries or concerning any
product relating to the businesses of the Company and its Subsidiaries which is
pending or, to the Company's knowledge, threatened, relating to or resulting
from an alleged defect in design, manufacture, materials or workmanship of any
product designed, manufactured, distributed, or sold by or on behalf of the
Company or any of its Subsidiaries (past or present), or any alleged failure to
warn, or from any alleged breach of express or implied warranties or
representations, (ii) to the Company's knowledge, during the past five years,
there has not been any Occurrence
-26-
<PAGE>
and (iii) other than any product not designed or manufactured by the Company or
any of its Subsidiaries the Recall of or subsequent corrective action for which
would not have a Company Material Adverse Effect, during the past five years,
there has not been any product recall or post-sale warning (collectively,
"RECALLS") by the Company or any of its Subsidiaries concerning any products
relating to the businesses of the Company and its Subsidiaries which were
designed, manufactured, marketed, distributed, or sold by the businesses of the
Company and its Subsidiaries (past or present), or to the of the Company's
knowledge, any investigation or any action that would require the consideration
by the Company's corrective action committee, made by any Person or entity
concerning whether to undertake or not to undertake any Recalls. The term
"OCCURRENCE" shall mean any accident, happening or event which is caused or
allegedly caused by any alleged hazard or alleged defect in manufacture, design,
materials or workmanship including, without limitation, any alleged failure to
warn or any breach of express or implied warranties or representations with
respect to, or any accident, happening or event otherwise involving, a product
(including any parts or components) relating to the businesses of the Company
and its Subsidiaries designed, manufactured, distributed, or sold by or on
behalf of the Company and its Subsidiaries which results or is alleged to have
resulted in injury or death to any Person or damage to or destruction of
property, or other consequential damages, at any time.
(b) Section 3.22(b) of the Company Disclosure Schedule
contains a true and complete list of (i) all products designed, manufactured,
marketed, distributed or sold by the Company or any of its Subsidiaries that
have been recalled or withdrawn (whether voluntarily or otherwise) at any time
during the past four years, other than any product not designed or manufactured
by the Company or any of its Subsidiaries the Recall or withdrawal of or
subsequent corrective action for which would not have a Company Material Adverse
Effect, and (ii) all proceedings known to the Company (whether completed or
pending) at any time during the past three years seeking the recall, withdrawal,
suspension or seizure of any product sold by the Company or any of its
Subsidiaries.
Section 3.23. SUPPLIERS AND CUSTOMERS. Since November 1, 1998,
except as set forth in Section 3.23 of the Company Disclosure Schedule, no
material licensor, vendor, supplier, licensee or customer of the Company or any
of its Subsidiaries has canceled or otherwise modified (in a manner materially
adverse to the Company) its relationship with the Company or its Subsidiaries
and, to the Company's knowledge, (i) no such Person has notified the Company of
its intention to do so, and (ii) the Company does not expect that the
consummation of the Transactions will adversely affect any of such
relationships.
Section 3.24. TITLE AND CONDITION OF PROPERTIES. The Company and its
subsidiaries own good and sufficient title, free and clear of all Liens, to all
of the personal property and assets shown on the Company Balance Sheet or
acquired after November 1, 1998, except for (A) assets which have been disposed
of to nonaffiliated third parties since November 1, 1998 in the ordinary course
of business, (B) Liens reflected in the Company Balance Sheet, (C) Liens or
imperfections of title which are not, individually or in the aggregate, material
in character, amount or extent and which do not materially detract from the
value or materially interfere with the present or presently contemplated use of
the assets subject thereto or affected thereby, and (D) Permitted Liens. All of
the machinery, equipment and other tangible personal property and assets owned
or used by the Company or its Subsidiaries are in good condition and repair,
except for ordinary wear and tear not caused by neglect, and are usable in the
ordinary course of business, except for
-27-
<PAGE>
any matter otherwise covered by this sentence which does not have, individually
or in the aggregate, a Company Material Adverse Effect.
Section 3.25. INFORMATION IN FINANCING DOCUMENTS. None of the
information supplied or to be supplied by the Company for the purpose of
inclusion or incorporation by reference in any syndication and other materials
to be delivered to potential financing sources in connection with the
transactions contemplated by this Agreement (the "FINANCING DOCUMENTS") will, at
the date delivered, contain any untrue statement of material fact contain any
untrue statement of a material fact or omit to state any material fact required
to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading.
Section 3.26. YEAR 2000 COMPLIANCE. The Company has adopted and
implemented a commercially reasonable plan to provide (x) that the change of the
year from 1999 to the year 2000 will not materially and adversely affect the
information and business systems of the Company or its Subsidiaries and (y) that
the impacts of such change on the vendors and customers of the Company and its
Subsidiaries will not have a the Company Material Adverse Effect. In the
Company's reasonable best estimate, no expenditures materially in excess of
currently budgeted items previously disclosed to Purchaser will be required in
order to cause the information and business systems of the Company and its
Subsidiaries to operate properly following the change of the year 1999 to the
year 2000. The Company reasonably expects that it will resolve any issues
related to such change of the year in accordance with the timetable set forth in
such plan (and in any event on a timely basis in order to be resolved before the
September 30, 1999). Between the date of this Agreement and the Effective Time,
the Company shall continue to use reasonable best efforts to implement such
plan.
ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF PURCHASER
Purchaser hereby represents and warrants to the Company as follows:
Section 4.1. ORGANIZATION. Purchaser is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Texas and has all requisite corporate or similar power and authority to own,
lease and operate its properties and to carry on its business as now being
conducted, except where the failure to be in good standing or to have such
corporate or similar power and authority would not in the aggregate have a
Purchaser Material Adverse Effect. Purchaser was formed on June 9, 1999 solely
for the purpose of engaging in the Transactions contemplated hereby. The term
"PURCHASER MATERIAL ADVERSE EFFECT" means any event, change, circumstance or
effect that is or could reasonably be expected to be materially adverse to the
ability of Purchaser to consummate the Transactions.
Section 4.2. AUTHORITY RELATIVE TO THIS AGREEMENT. Purchaser has all
necessary power and authority to execute and deliver this Agreement and to
consummate the Transactions. The execution and delivery of this Agreement and
the consummation of the Transactions have been duly and validly authorized by
the board of directors and stockholders of Purchaser, and no other
-28-
<PAGE>
corporate or similar proceedings on the part of Purchaser are necessary to
authorize this Agreement or to consummate the Transactions. This Agreement has
been duly and validly executed and delivered by Purchaser and, assuming due and
valid authorization, execution and delivery by the Company, constitutes a valid,
legal and binding agreement of Purchaser, enforceable against Purchaser in
accordance with its terms.
Section 4.3. CONSENTS AND APPROVALS; NO VIOLATIONS. Except for
filings, permits, authorizations, consents and approvals as may be required
under, and other applicable requirements of, the Securities Act, the Exchange
Act, state securities or blue sky laws, the HSR Act, and the filing and
recordation of an articles of merger as required by the TBCA, no filing with or
notice to, and no permit, authorization, consent or approval of, any
Governmental Entity is necessary for the execution and delivery by Purchaser of
this Agreement or the consummation by Purchaser of the Transactions, except
where the failure to obtain such permits, authorizations, consents or approvals
or to make such filings or give such notice would not have a Purchaser Material
Adverse Effect. Neither the execution, delivery and performance of this
Agreement by Purchaser nor the consummation by Purchaser of the Transactions
will (i) conflict with or result in any breach of any provision of the Articles
of Incorporation or bylaws of Purchaser or any of Purchaser's Subsidiaries, (ii)
result in a violation or breach of, or constitute (with or without due notice or
lapse of time or both) a default (or give rise to any right of termination,
amendment, cancellation or acceleration) under, any of the terms, conditions or
provisions of any note, bond, mortgage, indenture, lease, license, contract,
agreement or other instrument or obligation to which Purchaser or any of
Purchaser's Subsidiaries is a party or by which any of them or any of their
respective properties or assets may be bound or (iii) violate any order, writ,
injunction, decree, law, statute, rule or regulation applicable to Purchaser or
any of Purchaser's Subsidiaries or any of their respective properties or assets,
except in the case of (ii) or (iii) for violations, breaches or defaults which
would not, individually or in the aggregate, have a Purchaser Material Adverse
Effect.
Section 4.4. PROXY STATEMENT; OFFER DOCUMENTS. None of the
information supplied by Purchaser in writing specifically for inclusion in the
Proxy Statement or Form S-4 (if one is filed) or any of the Debt Offer Documents
will, at the respective times filed with the SEC and/or are first published or
sent or given to holders of Shares and/or Senior Notes, and in the case of the
Proxy Statement, at the time that it or any amendment or supplement thereto is
mailed to the Company's shareholders and, in the case of the Form S-4 (if one is
filed), at the time it becomes effective, at the time of the Shareholders'
Meeting or at the Effective Time, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading.
Section 4.5. FINANCING.
(a) At the Effective Time and subject to satisfaction of the
conditions in Article VI, (i) Purchaser will have cash funds from the issuance
of equity of not less than $107,000,000, and (ii) the Circon Buyer will have
cash funds from the issuance of equity of not less than $75,000,000 (in each
case pursuant to the equity commitment letters attached hereto as Exhibits A-1
and A-2, respectively).
-29-
<PAGE>
(b) Attached hereto as Exhibits B and C, respectively, are
(i) a commitment letter (the "HOLDCO COMMITMENT LETTER") from Fox Paine Capital
Fund, L.P. with respect to its obligation to purchase $50,000,000 of the
Company's Senior Notes and (ii) commitment letters and related documentation
(the "OPCO FINANCING COMMITMENT LETTERS" and together with the Holdco Commitment
Letter, the "COMMITMENT LETTER") from lenders relating to such debt financings
as is necessary, together with the funds referred to in paragraph (a) and
subparagraph (b)(i) above, to consummate the Debt Offer, the Merger and the
other Transactions (the "DEBT FUNDING").
(c) Purchaser represents that the terms and conditions of
the Commitment Letters are acceptable in form and substance to Purchaser.
Section 4.6. BROKERS. No broker, finder or investment banker is
entitled to any brokerage, finder's or other fee or commission payable by the
Company in connection with the Transactions based upon arrangements made by and
on behalf of Purchaser other than any payable upon consummation of the Debt
Offer and the Merger.
ARTICLE V
COVENANTS
Section 5.1. SHAREHOLDERS MEETING. The Company, acting through the
Board, will, as promptly as practicable following the date of this Agreement and
in consultation with Purchaser, (i) duly call, give notice of, convene and hold
a meeting of its shareholders for the purpose of considering and approving this
Agreement and the transactions contemplated hereby (the "SHAREHOLDERS MEETING")
and (ii) (A) include in the Proxy Statement the unanimous recommendation of the
Board that the shareholders of the Company vote in favor of the approval of this
Agreement and the other Transactions contemplated hereby and the written opinion
of the Financial Advisor that the consideration to be received by the
shareholders of the Company (other than Purchaser, its stockholders and the
Specified Shareholders) pursuant to the Merger is fair to such shareholders and
(B) use its best efforts to obtain the necessary approval of this Agreement and
the transactions contemplated hereby by its shareholders.
Section 5.2. PROXY STATEMENT. Promptly following the date of this
Agreement, the Company shall prepare the Proxy Statement, and, if necessary, the
Company shall prepare and file with the SEC the Form S-4, in which the Proxy
Statement would be included. If the Form S-4 is filed, the Company shall use its
best efforts as promptly as practicable to have the Form S-4 declared effective
under the Securities Act as promptly as practicable after such filing. The
Company shall use its best efforts to cause the Proxy Statement to be mailed to
the Company's shareholders as promptly as practicable or, if the Form S-4 is
filed, as promptly as practicable after the Form S-4 is declared effective under
the Securities Act. If the S-4 is filed, the information provided by the Company
for use in the Form S-4, and to be supplied by Purchaser in writing specifically
for use in the Form S-4, shall, at the time the Form S-4 becomes effective and
on the date of the Shareholders Meeting referred to above, be true and correct
in all material respects and shall not omit to state any material fact required
to be stated therein or necessary in order to make such information not
misleading, and the Company and Purchaser each agree to correct any
-30-
<PAGE>
information provided by it for use in the Proxy Statement or the Form S-4 which
shall have become false or misleading. Purchaser and the Company will cooperate
with each other in the preparation of the Proxy Statement and the Form S-4 (if
one is filed); without limiting the generality of the foregoing, the Company
will immediately notify Purchaser of the receipt of any comments from the SEC
and any request by the SEC for any amendment to the Proxy Statement or the Form
S-4 or for additional information. All filings with the SEC, including the Proxy
Statement and the Form S-4 (if filed) and any amendment thereto, and all
mailings to the Company's shareholders in connection with the Merger, including
the Proxy Statement, shall be subject to the prior review, comment and approval
of Purchaser (which approval by Purchaser shall not be unreasonably withheld).
Purchaser will furnish to the Company the information relating to it required by
the Exchange Act and the rules and regulations promulgated thereunder to be set
forth in the Proxy Statement. The Company agrees to use its best efforts, after
consultation with the other parties hereto, to respond promptly to any comments
made by the SEC with respect to the Form S-4 (if filed) or Proxy Statement and
any preliminary version thereof filed by it and cause such Proxy Statement to be
mailed to the Company's shareholders at the earliest practicable time.
Section 5.3. CONDUCT OF BUSINESS OF THE COMPANY. Except as expressly
contemplated by this Agreement, the Board will not permit the Company or any of
its Subsidiaries to conduct its operations otherwise than in the ordinary course
of business consistent with past practice. Without limiting the generality of
the foregoing, and except as otherwise expressly contemplated by this Agreement,
the Board will not, without the prior written consent of Purchaser, permit the
Company or any of its Subsidiaries to:
(a) amend or propose to amend its articles of incorporation
or bylaws;
(b) authorize for issuance, issue, sell, deliver, or agree
or commit to issue, sell or deliver, dispose of, encumber or pledge (whether
through the issuance or granting of options, warrants, commitments,
subscriptions, rights to purchase or otherwise) any stock of any class or any
securities, except as required by agreements with the Company's employees under
the Company Stock Plans as in effect as of the date hereof or pursuant to the
Rights Agreement, or amend any of the terms of any such securities or agreements
outstanding as of the date hereof, except as specifically contemplated by this
Agreement;
(c) split, combine or reclassify any shares of its capital
stock, declare, set aside or pay any dividend or other distribution (whether in
cash, stock or property or any combination thereof) in respect of its capital
stock, or redeem or otherwise acquire any of its securities or any securities of
its Subsidiaries;
(d) (i) incur or assume any long-term or short-term debt or
issue any debt securities except for borrowings under the Credit Agreement in
the ordinary course of business and in amounts not material to the Company and
its Subsidiaries taken as a whole; (ii) assume, guarantee, endorse or otherwise
become liable or responsible (whether directly, contingently or otherwise) for
the obligations of any other Person; (iii) make any loans, advances or capital
contributions to, or investments in, any other Person (other than to wholly
owned Subsidiaries of the Company or customary loans or advances to employees in
the ordinary course of business consistent with past practice and in amounts not
material to the maker of such loan or advance)
-31-
<PAGE>
or make any change in its existing borrowing or lending arrangements for or on
behalf of any such Person, whether pursuant to an employee benefit plan or
otherwise; (iv) pledge or otherwise encumber shares of capital stock of the
Company or any of its Subsidiaries; or (v) mortgage or pledge any of its
material assets, tangible or intangible, or create or suffer to exist any
material Lien thereupon;
(e) adopt a plan of complete or partial liquidation or adopt
resolutions providing for the complete or partial liquidation, dissolution,
consolidation, merger, restructuring or recapitalization of the Company or any
of its Subsidiaries;
(f) (i) except as may be required by law or as contemplated
by this Agreement, enter into, adopt or pay, agree to pay, grant, issue,
accelerate or accrue salary or other payments or benefits pursuant to, or amend
or terminate any bonus, profit sharing, compensation, severance, termination,
stock option, stock appreciation right, restricted stock, performance unit,
stock equivalent, stock purchase agreement, pension, retirement, deferred
compensation, employment, severance, welfare, insurance or other employee
benefit agreement, trust, plan, fund or other arrangement for the benefit or
welfare of any director, officer or employee in any manner, or (ii) (except for
normal increases in the ordinary course of business consistent with past
practice for employees (other than officers and directors) that, in the
aggregate, do not result in a material increase in benefits or compensation
expense to the Company, and as required under existing agreements or in the
ordinary course of business consistent with past practice) increase in any
manner the compensation or fringe benefits of any director, officer or employee
or pay any benefit not required by any plan and arrangement as in effect as of
the date hereof (including, without limitation, the granting of stock
appreciation rights or performance units);
(g) except as contemplated by Section 5.6(d), acquire, sell,
transfer, lease, encumber or dispose of any assets outside the ordinary course
of business or any assets which in the aggregate are material to the Company and
its Subsidiaries taken as a whole, or enter into any commitment or transaction
outside the ordinary course of business consistent with past practice which
would be material to the Company and its Subsidiaries taken as a whole;
(h) except as may be required as a result of a change in law
or in GAAP, change any of the accounting principles or practices used by it;
(i) revalue in any material respect any of its assets,
including, without limitation, writing down the value of inventory or
writing-off notes or accounts receivable other than in the ordinary course of
business;
(j) (A) acquire (by merger, consolidation, or acquisition of
stock or assets) any corporation, partnership or other business organization or
division thereof or any equity interest therein; (B) enter into any contract or
agreement other than in the ordinary course of business consistent with past
practice which would be material to the Company and its Subsidiaries taken as a
whole; (C) authorize any new capital expenditure or expenditures which,
individually, is in excess of $500,000 or, in the aggregate, are in excess of
$5,000,000; or (D) enter into or amend any contract, agreement, commitment or
arrangement providing for the taking of any action that would be prohibited
hereunder;
-32-
<PAGE>
(k) make any Tax election or settle or compromise any Tax
liability of the Company or any of its Subsidiaries, except if such action is
taken in the ordinary course of business consistent with past practice, and, in
any event, the Company shall consult with Purchaser before filing or causing to
be filed any Tax Return of the Company or any of its Subsidiaries and before
executing or causing to be executed any agreement or waiver extending the period
for assessment or collection of any Taxes of the Company or any of its
Subsidiaries;
(l) pay, discharge or satisfy any claims, liabilities or
obligations (absolute, accrued, asserted or unasserted, contingent or
otherwise), other than the payment, discharge or satisfaction in the ordinary
course of business consistent with past practice;
(m) permit any insurance policy naming it as a beneficiary
or a loss payable payee to be canceled or terminated without notice to Purchaser
except in the ordinary course of business and consistent with past practice
unless the Company shall have obtained a comparable replacement policy;
(n) except in the ordinary course of business consistent
with past practice, terminate, amend or modify, or waive any material provision
of, any of the Material Contracts;
(o) settle or compromise any pending or threatened material
suit, action or claim;
(p) enter into any agreement containing any provision or
covenant limiting the ability of the Company or any of its Subsidiaries to (i)
sell any products or services of or to any other Person, (ii) engage in any line
of business or (iii) compete with or to obtain products or services from any
Person or limiting the ability of any Person to provide products or services to
the Company or any of its Subsidiaries, in each case in any geographic area or
during any period of time; or
(q) take, or agree in writing or otherwise to take, any of
the actions described in Sections 5.3(a) through 5.3(p) or any action which
would make any of the representations or warranties of the Company contained in
this Agreement untrue or incorrect as of the date when made or would result in
any of the conditions set forth in Article VI not being satisfied.
Section 5.4. NO SOLICITATION.
(a) The Company agrees that, during the term of this
Agreement, it shall not, and shall not authorize or permit any of its
Subsidiaries or any of its or its Subsidiaries' directors, officers, employees,
agents or representatives, directly or indirectly, to solicit, initiate,
encourage or facilitate, or furnish or disclose non-public information in
furtherance of, any inquiries or the making of any proposal with respect to any
recapitalization, merger, consolidation or other business combination involving
the Company, or acquisition of any capital stock (other than upon exercise of
Stock Options which are outstanding as of the date hereof) or any material
portion of the assets (except for acquisitions of assets in the ordinary course
of business consistent with past practice) of the Company and its Subsidiaries,
or any combination of the foregoing (a "COMPETING TRANSACTION"), or negotiate,
explore or otherwise engage in discussions with any Person (other than
Purchaser, persons controlling Purchaser, or their respective directors,
officers, employees, agents and representatives) with respect to any Competing
Transaction or enter into any
-33-
<PAGE>
agreement, arrangement or understanding requiring or causing it to abandon,
terminate or fail to consummate the Debt Offer, the Merger or any of the other
Transactions contemplated by this Agreement; PROVIDED that, prior to the
Effective Time, if the Company receives a written proposal for a Competing
Transaction (x) that was not initiated, solicited or encouraged after the date
of this Agreement by the Company, its Subsidiaries or any of its or their
directors, officers, employees, agents or representatives and does not violate
or breach any confidentiality, exclusivity or standstill agreement executed by
the Company prior to the date of this Agreement (provided that the Company may
amend any standstill or similar provision of any such agreement solely to
provide or make clear that such third party may deliver to the Board a written
proposal for a Competing Transaction) and (y) that the Board or a special
committee thereof determines in good faith by majority vote could reasonably be
expected to result in a third party making a proposal for a Superior Transaction
(as defined in Section 5.4(b)), and subject to compliance with the last two
sentences of this Section 5.4(a), the Company may (A) furnish information with
respect to the Company to the Person making such proposal pursuant to a
customary confidentiality agreement the terms of which shall be no less
favorable to the Company than the confidentiality agreement entered into by the
Company on or after January 1, 1999 that is most favorable to the Company, and
(B) participate in discussions or negotiations with such Person regarding such
proposal. The activities referred to in clauses (A) and (B) of the previous
sentence, if undertaken in strict compliance with all of the terms and
conditions of the previous sentence, are referred to herein as "Permitted
Discussions". In no event shall the Company furnish (or authorize any of its
Subsidiaries, or any of its or its Subsidiaries' directors, officers, employees,
agents or representatives, directly or indirectly, to furnish) to any competitor
or potential competitor of the Company or its Subsidiaries information about the
Company or any of its Subsidiaries unless the Board or a special committee
thereof determines in its reasonable judgment, after consultation with
management, that disclosure of such information would not be materially
competitively disadvantageous to the Company and its Subsidiaries, including,
without limitation, pricing, volume, sales and marketing information ("Sensitive
Information"); PROVIDED that the Company may provide Sensitive Information to a
competitor or potential competitor of the Company if confirmatory review of
Sensitive Information is the only remaining condition to the Company and such
competitor or potential competitor entering into an Acquisition Agreement (as
defined in Section 5.4(b)) with respect to a Superior Transaction that has been
approved by the Board and approved (subject only to such confirmatory review) by
the board of directors (or similar governing body) of such competitor or
potential competitor. The Company shall, and shall cause its Subsidiaries and
their respective directors, officers, employees, agents and representatives
immediately to cease all existing activities, discussions and negotiations with
any parties conducted heretofore with respect to any of the foregoing. Neither
the Board nor any committee thereof shall (A) withdraw or modify, or propose
publicly to withdraw or modify, in a manner adverse to Purchaser, the Company
Board Recommendation, or (B) approve or recommend, or propose publicly to
approve or recommend, any Competing Transaction. Notwithstanding the foregoing,
in the event that prior to the Effective Time the Board receives the advice of
its outside legal counsel that failure to do so will result in breach of its
fiduciary duties to the shareholders of the Company under applicable law, the
Board may (subject to this and the following sentences of this Section 5.4(a))
withdraw or modify the Company Board Recommendation, provided that it gives
Purchaser five days' prior written notice of its intention to do so. Any such
withdrawal or modification of the Company Board Recommendation shall not change
the approval of the Board for purposes of causing any state takeover statute or
other state law to be
-34-
<PAGE>
inapplicable to the transactions contemplated hereby, or change the obligation
of the Company to present the Merger for approval and adoption by shareholders
of the Company or to hold the Debt Offer open. From and after the execution of
this Agreement, the Company shall immediately advise Purchaser in writing of the
receipt, directly or indirectly, of any inquiries, discussions, negotiations, or
proposals relating to a Competing Transaction (including the specific terms
thereof and the identity of the other party or parties involved) and promptly
furnish to Purchaser a copy of any such proposal or inquiry in addition to any
information provided to or by any third party relating thereto. The Company
shall keep Purchaser fully apprised of the status of any proposal relating to a
Competing Transaction on a current basis, including, without limitation,
promptly providing to Purchaser any Sensitive Information provided to any
competitor or potential competitor pursuant to this paragraph (a).
(b) If prior to the Effective Time the Board shall determine
in good faith, after consultation with its financial and legal advisors, that
any bona fide written proposal from a third party for a Competing Transaction
received after the date hereof that was not initiated, solicited or encouraged
by the Company or any of its Subsidiaries or their respective directors,
officers, employees, agents or representatives in violation of this Agreement
and that does not violate or breach any confidentiality, exclusivity or
standstill agreement executed by the Company prior to the date of this Agreement
(as any such agreement may be amended in accordance with Section 5.4(a)) is more
favorable to the shareholders of the Company from a financial point of view than
the transactions contemplated by this Agreement (including any adjustment to the
terms and conditions of such transaction proposed in writing by Purchaser in
response to such Competing Transaction), is likely to and capable of being
consummated, and is in the best interest of the shareholders of the Company, and
the Company has received (x) advice of its outside legal counsel that failure to
enter into such a Competing Transaction will constitute a breach of the Board of
Directors' fiduciary duties under applicable law and (y) a written opinion (a
copy of which has been delivered to Purchaser) from the Financial Advisor (or
any other nationally recognized investment banking firm), that the Competing
Transaction is more favorable from a financial point of view to the shareholders
of the Company (other than Purchaser and the Specified Shareholders) than the
transactions contemplated by this Agreement (including any adjustment to the
terms and conditions of such transaction proposed in writing by Purchaser) (a
"Superior Transaction"), the Company may terminate this Agreement and enter into
a letter of intent, agreement-in-principle, acquisition agreement or other
similar agreement (each, an "ACQUISITION AGREEMENT") with respect to such
Superior Transaction provided, that, prior to any such termination, (i) the
Company has provided Purchaser written notice that it intends to terminate this
Agreement pursuant to this Section 5.4(b), identifying the Superior Transaction
then determined to be more favorable and the parties thereto and delivering a
copy of the Acquisition Agreement for such Competing Transaction in the form to
be entered into, and (ii) at least five full business days after the Company has
provided the notice referred to in clause (i) above (provided that the opinions
referred to in clauses (x) and (y) above shall continue in effect without
revision or modification), the Company delivers to Purchaser (A) a written
notice of termination of this Agreement pursuant to this Section 5.4(b), and (B)
a check or wire transfer of same day funds in an amount equal to the Purchaser
Expenses (as the same may have been estimated by Purchaser in good faith prior
to the date of such delivery (subject to an adjustment payment between the
parties upon Purchaser's definitive determination of such expenses)) plus the
amount of the Termination Fee as provided in Section 7.2, and (C) Purchaser
receives a written acknowledgment from the Com-
-35-
<PAGE>
pany and from the other party to a Superior Transaction that the Company and
such other party have irrevocably waived any right to contest such payments.
Section 5.5. ACCESS TO INFORMATION.
(a) Between the date hereof and the Effective Time, the
Company will give Purchaser and its authorized representatives and Persons
providing or committed or proposing to provide Purchaser or the Company with
financing for the Transactions and their representatives, reasonable access to
all employees, plants, offices, warehouses and other facilities and properties
and to all books and records of the Company and its Subsidiaries, will permit
Purchaser and its authorized representatives to make such inspections (including
any physical inspections or soil or groundwater investigations), at Purchaser's
expense, as they may reasonably request and will cause the Company's officers
and employees and those of its Subsidiaries to furnish Purchaser with such
financial and operating data and other information with respect to the business
and properties of the Company and any of its Subsidiaries as Purchaser may from
time to time reasonably request.
(b) Prior to the Effective Time, the Company and its
accountants, counsel, agents and other representatives shall cooperate with
Purchaser by providing information about the Company which is necessary for
Purchaser and its accountants, agents, counsel and other representatives to
participate in and to assist the Company in preparing the Financing Documents
and such other documents and other reasonable requests with respect to such
documents. Notwithstanding anything in this Agreement to the contrary, to the
extent reasonably appropriate to assist the success of the financing for the
Transactions, Purchaser may disclose, or cause its representatives to disclose,
and at the request of Purchaser, the Company shall disclose information
concerning the Company and its Subsidiaries and their respective businesses,
assets and properties, and the Transactions in the Financing Documents and to
prospective financing sources in connection with the Transactions.
(c) Except as otherwise agreed to by the Company, until the
earlier of the Effective Time and the second anniversary of the date hereof, and
notwithstanding termination of this Agreement, Purchaser will keep, and will
instruct its officers, employees, independent accountants, counsel, financial
advisers and other representatives and affiliates (x) to keep, all Confidential
Information (as defined below) confidential, (y) not to disclose any
Confidential Information to any Person other than the directors, officers,
employees, affiliates or agents of Purchaser and of Persons controlling
Purchaser, and then only on a confidential basis, and (z) to use Confidential
Information solely in connection with (A) the evaluation of, preparation for,
and consummation of the Transactions and (B) seeking or obtaining financing for
the Transactions; PROVIDED, HOWEVER, that Purchaser may disclose Confidential
Information (i) as required by law, rule, regulation or judicial process,
including as required to be disclosed in connection with the Merger, the Debt
Funding or any other Transaction, (ii) to its financing sources and to
Purchaser's and such financing sources' attorneys, accountants, and financial
advisors or (iii) as requested or required by any Governmental Entity. For
purposes of this Agreement, "Confidential Information" shall include all
confidential information about the Company which has been furnished by the
Company to Purchaser or the directors, officers, employees, affiliates or agents
of Purchaser or Persons controlling Purchaser pursuant to or in connection with
the negotiation, execution and consummation of this Agreement; PROVIDED,
HOWEVER, that Confidential Informa-
-36-
<PAGE>
tion does not include information which (x) is or becomes generally available to
the public other than as a result of a disclosure by Purchaser not permitted by
this Agreement, (y) was available to Purchaser on a non-confidential basis prior
to its disclosure to Purchaser by the Company or (z) becomes available to
Purchaser on a non-confidential basis from a Person (other than the Company)
who, to the knowledge of Purchaser, is not otherwise bound by a confidentiality
agreement with the Company or is not otherwise prohibited from transmitting the
relevant information to Purchaser. The provisions of this paragraph (c) are
referred to herein as the "Confidentiality Provisions".
Section 5.6. ADDITIONAL AGREEMENTS, REASONABLE EFFORTS.
(a) Prior to the Effective Time, upon the terms and subject
to the conditions of this Agreement, each of Purchaser and the Company, agrees
to use its reasonable efforts to take, or cause to be taken, all actions, and to
do, or cause to be done, all things necessary, proper or advisable under any
applicable laws, rules or regulations to consummate and make effective the
Transactions as promptly as practicable including, but not limited to, (i) the
preparation and filing of all forms, registrations and notices required to be
filed to consummate the Transactions and the taking of such actions as are
necessary to obtain any requisite approvals, consents, orders, exemptions or
waivers by any third party or Governmental Entity, (ii) the preparation of any
Financing Documents reasonably requested by Purchaser and (iii) the satisfaction
of the other parties' conditions to the consummation of the Debt Offer or the
Closing. In addition, no party hereto shall take any action after the date
hereof that would reasonably be expected to materially delay the obtaining of,
or result in not obtaining, any permission, approval or consent from any
Governmental Entity necessary to be obtained prior to the consummation of the
Closing. The Company agrees to use its reasonable efforts to assist Purchaser in
connection with structuring or obtaining any financing for Purchaser and/or the
Company and its Subsidiaries in connection with consummation of the
Transactions, and Purchaser shall use its reasonable efforts to obtain such
financing for Purchaser and/or the Company and its Subsidiaries. At the request
of Purchaser from time to time, the Company agrees to use its reasonable efforts
to cause members of its senior management to participate in any "roadshow" or
other presentations to potential investors in connection with the obtaining of
any financing for Purchaser and/or the Company and its Subsidiaries in
connection with the Transactions.
(b) Prior to the Effective Time, each party shall promptly
consult with the other parties hereto with respect to, provide any necessary
information with respect to and provide the other (or its counsel) copies of,
all filings made by such party with any Governmental Entity or any other
information supplied by such party to a Governmental Entity in connection with
this Agreement and the Transactions. Each party hereto shall promptly inform the
other of any communication from any Governmental Entity regarding any of the
Transactions. If any party hereto or affiliate thereof receives a request for
additional information or documentary material from any such Governmental Entity
with respect to the Transactions, then such party will endeavor in good faith to
make, or cause to be made, as soon as reasonably practicable and after
consultation with the other party, an appropriate response in compliance with
such request. To the extent that transfers of Company Permits are required as a
result of execution of this Agreement or consummation of the Transactions, the
Company and Purchaser shall use all reasonable efforts to effect such transfers.
-37-
<PAGE>
(c) Notwithstanding the foregoing, nothing in this Agreement
shall be deemed to require Purchaser or any of its affiliates to (i) enter into
any agreement with any Governmental Entity or to consent to any order, decree or
judgment requiring Purchaser to hold separate or divest, or to restrict the
dominion or control of Purchaser or any of its affiliates over, any of the
assets, properties of businesses of Purchaser, its affiliates or the Company or
any of its Subsidiaries, in each case as in existence on the date hereof, or
(ii) defend against any litigation brought by any Governmental Entity seeking to
prevent the consummation of the Transactions.
(d) The parties hereto agree that substantially concurrent
with the Closing, unless otherwise requested by Purchaser, the Company shall, or
shall cause its appropriate Subsidiary to, sell and convey all of the
outstanding capital stock of Circon to an affiliate of Purchaser (the "CIRCON
BUYER") on the terms previously disclosed to the Company by Purchaser and as
contemplated by the Financing Documents and the Management Rollover Plan (as
defined in Section 6.1(b)) or on such other terms as Purchaser shall reasonably
request, and the parties hereto agree to execute any agreement, amendment or
other documentation necessary or desirable to accomplish such structure
modification (including modifications to any financing arrangements)
(collectively, the "CIRCON SALE"); PROVIDED that the Company shall not be
required to take any action or enter into any agreement or amendment that would
have the effect of reducing the Per Share Amount or otherwise reducing the
consideration to be received by holders of Company Common Stock (other than
Purchaser or the Specified Shareholders).
(e) Provided that any such action does not have a Purchaser
Material Adverse Effect or materially delay the Closing, then any other
provision of this Agreement to the contrary notwithstanding, Purchaser may amend
or revise the Commitment Letters, amend, increase, decrease or replace any
component of the Debt Funding or other financings referred to in Section 4.5, or
enter into new, replacement or additional financing arrangements, through itself
or any affiliate of itself or of persons controlling Purchaser, in connection
with the Debt Funding or other financings referred to in Section 4.5 or
otherwise to facilitate the transactions contemplated by this Agreement.
Section 5.7. PUBLIC ANNOUNCEMENTS. Purchaser and the Company, as the
case may be, will consult with each other before issuing any press release or
otherwise making any public statements with respect to the Transactions,
including, without limitation, the Debt Offer and the Merger, and shall not
issue any such press release or make any such public statement prior to such
consultation (and shall give reasonable consideration given to the comments of
the other), in each case except as may be required by applicable law or by
obligations pursuant to any listing agreement with any national securities
exchange, as determined by Purchaser or the Company, as the case may be.
Section 5.8. INDEMNIFICATION.
(a) Purchaser agrees that all rights to indemnification or
exculpation now existing in favor of the directors, officers, employees and
agents of the Company and its Subsidiaries as provided in their respective
charters or bylaws or otherwise in effect as of the date hereof with respect to
matters occurring prior to the consummation of the last to occur of any of the
Transactions shall survive such consummation and shall continue in full force
and effect.
-38-
<PAGE>
(b) Purchaser shall cause the Company or the Surviving
Corporation, as the case may be, to maintain in effect for not less than six
years from the Effective Time, the policies of the directors' and officers'
liability and fiduciary insurance most recently maintained by the Company with
respect to matters occurring prior to the Effective Time to the extent
available; PROVIDED that (i) the Surviving Corporation may substitute therefor
policies of at least the same coverage containing terms and conditions which are
no less advantageous to the beneficiaries thereof so long as such substitution
does not result in gaps or lapses in coverage, and (ii) such policies may in the
sole discretion of the Company after the Effective Time be one or more "tail"
policies for all or any portion of the full six year period; and, PROVIDED,
FURTHER, that in no event shall the Company or the Surviving Corporation, as the
case may be, be required to expend more than an amount per year equal to 150% of
the current annual premiums paid by the Company (the "PREMIUM AMOUNT") to
maintain or procure insurance coverage pursuant hereto and further provided that
if the Surviving Corporation is unable to obtain the insurance called for by
this Section 5.8(b), the Surviving Corporation will obtain as much comparable
insurance as is available for the Premium Amount per year.
Section 5.9. RECAPITALIZATION. The Company shall cooperate with any
reasonable requests of Purchaser or the SEC related to the reporting of the
Transactions as a recapitalization for financial reporting purposes including,
without limitation, to assist Purchaser and its affiliates with any presentation
to the SEC with regard to such reporting and to include appropriate disclosure
with regard to such reporting in all filings with the SEC and mailing to the
shareholders of the Company made in connection with the Debt Offer or the
Merger. In furtherance of the foregoing, the Company shall provide to Purchaser
for the prior review of Purchasers advisors any description of Transactions
which is meant to be disseminated.
Section 5.10. FINANCIAL STATEMENTS. The Company shall promptly
prepare at the end of each month and promptly deliver to Purchaser upon
completion the balance sheet, income statement and statement of cash flows
prepared in accordance with GAAP of the Company and Circon for each month ended
between the date of this Agreement and the Effective Time. The Company shall
promptly prepare all reasonably requested financial statements required to be
included in the Financing Documents.
Section 5.11. CERTAIN AGREEMENTS WITH MANAGEMENT. (a) Neither
Purchaser nor any of its affiliates shall enter into any agreement, arrangement
or understanding that would have the effect (i) of prohibiting any Specified
Shareholder who is an officer of the Company from participating in Permitted
Discussions with any third party at any time during which the Company is
permitted to engage (and is so engaging) in such discussions with such third
party pursuant to Section 5.4(a), or (ii) of prohibiting or preventing any
Specified Shareholder, at any time after any termination of this Agreement in
accordance with its terms, from participating in (as a shareholder, employee, or
both) a Superior Transaction.
(a) Neither Purchaser nor any of its affiliates shall enter
into any agreement, arrangement or understanding with any or all of the
Specified Shareholders if such agreement, arrangement or understanding would
jeopardize the ability of the condition set forth in Section 6.1(b)(vi) to be
satisfied.
-39-
<PAGE>
ARTICLE VI
CONDITIONS TO CONSUMMATION OF THE MERGER
Section 6.1. CONDITIONS TO THE MERGER.
(a) The obligation of the Company to consummate the Merger
is subject to the satisfaction (or waiver) at or prior to the Effective Time of
each of the following conditions:
(i) ACCURACY OF REPRESENTATIONS AND WARRANTIES. All
representations and warranties made by Purchaser herein shall
be true and correct in all material respects (except for
representations qualified by materiality or Purchaser Material
Adverse Effect which shall be correct in all respects) on the
Closing Date, with the same force and effect as though such
representations and warranties had been made on and as of the
Closing Date, except for representations and warranties that
are made as of a specified date or time, which shall be true
and correct in all material respects (except for
representations qualified by materiality or Purchaser Material
Adverse Effect which shall be correct in all respects) only as
of such specific date or time.
(ii) COMPLIANCE WITH COVENANTS. Purchaser shall have
performed in all material respects all obligations and
agreements, and complied in all material respects with
covenants, contained in this Agreement to be performed or
complied with by it prior to or on the Closing Date.
(iii) OFFICER'S CERTIFICATES. The Company shall have
received certificates of Purchaser, dated as of the Closing
Date, signed by an executive officer of Purchaser to evidence
satisfaction of the conditions set forth in Section 6.1(a)(i)
and (ii).
(iv) SOLVENCY OPINION. The Company shall have received
an independent solvency opinion substantially similar to (or,
if addressed to the Company, a copy of) the insolvency letter
to be delivered to the lenders pursuant to the terms of the
Commitment Letters.
(b) The obligation of Purchaser to consummate the Merger is
subject to the satisfaction (or waiver) at or prior to the Effective Time of
each of the following conditions:
(i) ACCURACY OF REPRESENTATIONS AND WARRANTIES. All
representations and warranties made by the Company herein shall
be true and correct in all material respects, (except for
representations qualified by materiality or Company Material
Adverse Effect which shall be correct in all respects) on the
Closing Date, with the same force and effect as though such
representations and warranties had been made on and as of the
Closing Date, except for representations and warranties that
are made as of a specified date or time, which shall be true
and correct in all material respects (except for
representations qualified by materiality or Company Material
Adverse Effect which shall be correct in all respects) only as
of such specific date or time.
(ii) COMPLIANCE WITH COVENANTS. The Company shall have
performed in all material re-
-40-
<PAGE>
spects all obligations and agreements, and complied in all
material respects with covenants, contained in this
Agreement to be performed or complied with by it prior to or
on the Closing Date.
(iii) OFFICER'S CERTIFICATE. Purchaser shall have
received a certificate of the Company, dated as of the Closing
Date, signed by an executive officer of the Company to evidence
satisfaction of the conditions set forth in Section 6.1(b)(i)
and (ii).
(iv) DEBT OFFER. The conditions to the Debt Offer set
forth in Annex A shall have been satisfied, the terms of the
Senior Notes and the Senior Notes Indenture shall have been
amended in accordance with the Senior Notes Amendments, and the
Company shall concurrently with the Closing, purchase all
Senior Notes validly tendered and not withdrawn pursuant to the
Debt Offer.
(v) CIRCON CLOSING. Unless otherwise requested by
Purchaser, the closing of the Circon Sale shall occur
substantially concurrently with the Closing.
(vi) RECAPITALIZATION ACCOUNTING. The Company shall
have received from the Company's regular independent auditing
firm a letter in form and substance reasonably satisfactory to
Purchaser to the effect that the transactions contemplated by
this Agreement will receive recapitalization accounting
treatment and such letter has not been modified in a manner
adverse to Purchaser or withdrawn.
(vii) NO LITIGATION. There shall not be pending any
suit, action or proceeding by any Governmental Entity or any
other person that has a reasonable likelihood of success, (i)
seeking to prohibit or impose any material limitations on
Purchaser's ownership or operation of all or a material portion
of their or the Company's businesses or assets (or those of any
of its Subsidiaries or affiliates), or to compel Purchaser or
the Company or their respective Subsidiaries and affiliates,
before or after the Effective Time, to dispose of or hold
separate any material portion of the business or assets of the
Company and its Subsidiaries, taken as a whole, (ii)
prohibiting, restricting or significantly delaying consummation
of the Debt Offer or the Merger or the performance of any of
the other Transactions, or seeking to obtain from Purchaser (or
its affiliates) or the Company (or its affiliates) any damages
that are material, respectively, in relation to Purchaser
(assuming Purchaser has assets equal to the amount of cash it
is required to have at the Effective Time pursuant to Section
4.5(a)) or the Company and its Subsidiaries as taken as a
whole, (iii) seeking to impose material limitations on the
ability of Purchaser or its affiliates, or render Purchaser or
its affiliates unable, to acquire or hold or to exercise
effectively all rights of ownership of shares of Company Common
Stock, or effectively to control in any material respect the
business, assets or operations of the Company, its Subsidiaries
or Purchaser or any of their respective affiliates, or (iv)
which otherwise is reasonably likely to have a Company Material
Adverse Effect or a Purchaser Material Adverse Effect.
(viii)COMPANY MATERIAL ADVERSE EFFECT. From and after
the date of this Agreement, there shall not have occurred any
change, development or event that constitutes or has a Company
Material Adverse Effect.
-41-
<PAGE>
(ix) CONSENTS. There shall have been obtained any
consent, permit or approval the absence of which or the failure
of which to be obtained constitutes or has a Company Material
Adverse Effect or Purchaser Material Adverse Effect.
(x) DEBT FUNDING. The Debt Funding shall have been
obtained on terms and conditions acceptable in form and
substance to Purchaser (giving effect to Purchaser's
representations contained in Section 4.5(c)).
Section 6.2. CONDITIONS TO EACH PARTY'S OBLIGATIONS TO EFFECT THE
MERGER.
(a) The respective obligations of each party hereto to
effect the Merger is further subject to the satisfaction at or prior to the
Effective Time of each of the following conditions, any and all of which may be
waived in whole or in part by the parties hereto to the extent permitted by
applicable law:
(i) SHAREHOLDER APPROVAL. The Company Shareholder
Approval shall have been validly obtained under the TBCA and
the Company's articles of incorporation and bylaws.
(ii) STATUTES; COURT ORDERS. No statute, rule,
regulation, executive order, decree, ruling or injunction shall
have been enacted, entered, promulgated or enforced by any
Governmental Entity which prohibits, restrains, enjoins or
restricts the consummation of the Merger; and there shall be no
order or injunction of a court of competent jurisdiction in
effect precluding consummation of the Merger.
(iii) HSR APPROVAL. Any waiting period applicable to
the Merger or the Circon Sale under the HSR Act shall have
terminated or expired.
ARTICLE VII
TERMINATION; AMENDMENT; WAIVER
Section 7.1. TERMINATION. This Agreement may be terminated and the
Transactions may be abandoned at any time prior to the Effective Time
notwithstanding any requisite approval and adoption of this Agreement and the
Transactions by the shareholders of the Company:
(a) by mutual written consent duly authorized by the Board
of Directors of each of the Company and the Purchaser;
(b) by Purchaser or the Company if (i) any Governmental
Entity shall have issued a final order, decree or ruling (which order, decree or
ruling the parties hereto shall use all reasonable efforts to lift) or taken any
other final action restraining, enjoining or otherwise prohibiting the Debt
Offer, the Circon Sale or the Merger and such order, decree, ruling or other
action is or shall have become final and nonappealable, or (ii) the Effective
Time shall not have occurred on or before December 31, 1999 (the "OUTSIDE
DATE"); PROVIDED, HOWEVER, that the right to terminate this Agreement under this
Section 7.1(b)(ii) shall not be available to any party
-42-
<PAGE>
whose failure to fulfill any obligation under this Agreement has been the cause
of, or resulted in, the failure of the Effective Time to occur on or before such
date;
(c) by the Company, pursuant to and in strict compliance
with Section 5.4(b);
(d) by Purchaser, if (i) there shall have been a material
breach of any of the Company's representations, warranties or covenants which
breach (A) would give rise to the failure of a condition set forth in Section
6.1(b) or Section 6.2 and (B) cannot be or has not been cured within 30 days
following written notice of such breach, (ii) the Board shall withdraw, modify,
or change (including by amendment of the Proxy Statement) the Company Board
Recommendation or shall have publicly indicated its intention to do so in a
manner adverse to Purchaser, (iii) the Board shall have recommended any proposal
in respect of a Competing Transaction, (iv) any Person or group (as defined in
Section 13(d)(3) of the Exchange Act) other than Purchaser or any of its
respective subsidiaries or affiliates shall have become the beneficial owner of
more than 15% of the outstanding shares of Company Common Stock (either on a
primary or a fully diluted basis), or (v) the Company shall otherwise have
breached or taken any action in violation of Section 5.4;
(e) by the Company if there shall have been a material
breach of any of Purchaser's representations, warranties or covenants which
breach (A) would give rise to the failure of a condition set forth in Section
6.1(a) or Section 6.2 and (B) cannot be or has not been cured within thirty (30)
days following receipt of written notice of such breach; or
(f) by either Purchaser or the Company if at the
Shareholders Meeting (including any postponement or adjournment thereof) the
Company Shareholder Approval shall have not been obtained.
Section 7.2. EFFECT OF TERMINATION. In the event of the termination
and abandonment of this Agreement pursuant to Section 7.1, written notice
thereof shall forthwith be given to the other party or parties specifying the
provision hereof pursuant to which such termination is made, and this Agreement
shall forthwith become void and have no effect, without any liability on the
part of any party hereto or its affiliates, directors, officers or shareholders,
other than the provisions of this Section 7.2 and Section 7.3 hereof; PROVIDED,
HOWEVER, that nothing contained in this Section 7.2 shall relieve any party from
liability for any breach of this Agreement.
Section 7.3. FEES AND EXPENSES.
(a) In the event that (i) Purchaser shall have terminated
this Agreement pursuant to Section 7.1(b)(ii) and (A) the failure of the Company
to fulfill any obligation under this Agreement has been the cause of, or
resulted in, the failure of the Effective Time to occur on or before the Outside
Date and (B) on or prior to such time any entity or group (other than Purchaser
and its affiliates) shall have made and not withdrawn a proposal that is or
becomes publicly disclosed for (or publicly disclosed its intention to make a
proposal for) a Competing Transaction, (ii) Purchaser shall have terminated this
Agreement pursuant to Section 7.1(d)(ii), (iii), (iv) or (v), (iii) either party
shall have terminated this Agreement pursuant to Section 7.1(f) and on or prior
to the Shareholders Meeting any entity or group (other than Purchaser and its
affiliates) shall have made and not withdrawn a proposal that is or becomes
publicly disclosed for
-43-
<PAGE>
(or publicly disclosed its intention to make a proposal for) a Competing
Transaction, or (iv) the Company shall have terminated this Agreement pursuant
to 7.1(c) hereof, then the Company shall pay to Purchaser, a termination fee
(the "TERMINATION FEE"), in cash, of $19,000,000, PROVIDED, HOWEVER, that the
Company in no event shall be obligated to pay more than one such Termination Fee
with respect to all such agreements and occurrences and such termination. Any
Termination Fee that becomes payable shall be paid (x) in the case of clauses
(i) and (ii) above, within one business day following the occurrence of the
event giving rise to such payment, (y) in the case of clause (iii) above, at
least one business day prior to termination in the case of a termination by the
Company, and within one day following termination in the case of termination by
Purchaser, and (z) in the case of clause (iv) above, in accordance with Section
5.4(b).
(b) Provided that no Termination Fee has become payable to
Purchaser, upon the termination of this Agreement by the Company pursuant to
Section 7.1(c) or 7.1(f) or by Purchaser pursuant to Section 7.1(b)(ii) (in the
circumstance referred to in Section 7.3(a)(i)), 7.1(d) or 7.1(f), the Company
shall reimburse Purchaser and its affiliates (not later than one business day
after submission of statements therefor (or at such earlier time as may be
required pursuant to Section 5.4(b)) for all actual documented out-of-pocket
fees and expenses actually and reasonably incurred by any of them or on their
behalf in connection with the any of the transactions contemplated by this
Agreement (including, without limitation, fees and expenses payable to financing
sources, investment bankers, counsel to any of the foregoing, counsel to
Purchaser and its affiliates and accountants) (the "PURCHASER EXPENSES"), less
any such expenses previously reimbursed. The Company shall in any event pay the
amount requested within one business day of such request, subject to the
Company's right to demand a return of any portion as to which invoices are not
received in due course.
(c) Upon the consummation of the Merger, all costs and
expenses incurred by each party hereto in connection with this Agreement and the
transactions contemplated hereby (including, without limitation, fees and
disbursements of counsel, financial advisors and accountants) shall be paid by
the Company or the Company shall promptly reimburse each such party, as the case
may be
(d) Except as specifically provided in this Section 7.3 each
party shall bear its own expenses in connection with this Agreement and the
transactions contemplated by this Agreement.
Section 7.4. AMENDMENT. Subject to applicable law, this Agreement
may be amended by the parties hereto at any time before or after approval of the
Merger by the shareholders of the Company (if required by applicable law), but
after any such approval, no amendment shall be made which requires the approval
of such shareholders under applicable law without such approval. This Agreement
may not be amended except by an instrument in writing signed on behalf of the
parties hereto.
Section 7.5. WAIVER. At any time prior to the Effective Time, any
party hereto may (i) extend the time for the performance of any of the
obligations or other acts of the other party, (ii) waive any inaccuracies in the
representations and warranties of the other party contained herein or in any
document, certificate or writing delivered pursuant hereto, or (iii) waive
compliance by the other party with any of the agreements or conditions contained
herein. Any agreement on the
-44-
<PAGE>
part of any party hereto to any such extension or waiver shall be valid only if
set forth in an instrument in writing signed on behalf of such party. The
failure of either party hereto to assert any of its rights hereunder shall not
constitute a waiver of such rights.
ARTICLE VIII
MISCELLANEOUS
Section 8.1. NONSURVIVAL OF REPRESENTATIONS AND WARRANTIES. The
representations and warranties made herein shall not survive beyond the
Effective Time.
Section 8.2. ENTIRE AGREEMENT; ASSIGNMENT. This Agreement (including
the schedules and exhibits hereto), (a) constitutes the entire agreement among
the parties hereto with respect to the subject matter hereof and supersedes all
other prior agreements and understandings, both written and oral, between the
parties with respect to the subject matter hereof, including, without
limitation, that certain letter agreement dated April 8, 1999, between the
Company and Fox Paine & Company, LLC, and (b) shall not be assigned by operation
of law or otherwise; PROVIDED, HOWEVER, that Purchaser may assign any or all of
its rights and obligations under this Agreement to any Subsidiary or affiliate
of Purchaser, but no such assignment shall relieve Purchaser of its obligations
hereunder if such assignee does not perform such obligations.
Section 8.3. VALIDITY. If any provision of this Agreement, or the
application thereof to any Person or circumstance, is held invalid or
unenforceable, the remainder of this Agreement, and the application of such
provision to other Persons or circumstances shall not be affected thereby, and
to such end, the provisions of this Agreement are agreed to be severable.
Section 8.4. NOTICES. All notices, requests, claims, demands and
other communications hereunder shall be in writing (including by facsimile with
written confirmation thereof) and unless otherwise expressly provided herein,
shall be delivered during normal business hours by hand, by FedEx or other
nationally recognized overnight commercial delivery service, or by facsimile
notice, confirmation of receipt received, addressed as follows, or to such other
address as may be hereafter notified by the respective parties hereto:
(a) If to Purchaser:
Fox Paine Medic Acquisition Corporation
c/o Fox Paine & Company, LLC
950 Tower Lane, Suite 1950
Foster City, California 94404
Attention: Saul A. Fox
Facsimile: 650-525-1396
With a copy, which will not constitute notice, to:
Wachtell, Lipton, Rosen & Katz
51 West 52nd Street
New York, New York 10019
-45-
<PAGE>
Attention: Mitchell S. Presser
Facsimile: 212-403-2000
(b) If to the Company:
Maxxim Medical, Inc.
10300 49th Street North
Clearwater, Florida 33762
Attention: Kenneth W. Davidson
Facsimile: 727-561-2180
With a copy, which will not constitute notice, to:
Wolf, Block, Schorr and Solis-Cohen LLP
250 Park Avenue
New York, NY 10177
Attention: Herbert Henryson II
Facsimile: 212-986-0604
and
Shumaker, Loop & Kendrick, LLP
101 East Kennedy Boulevard
Barnett Plaza, Suite 2800
Tampa, FL 33602-5151
Attention: W. Thompson Thorn, III
Facsimile: 813-222-1705
Section 8.5. GOVERNING LAW. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, without regard
to the principles of conflicts of law thereof, except that matters pertaining to
the effectuation and effects of the Merger and the transactions provided for in
Section 2.1 shall be governed by and construed in accordance with the laws of
the State of Texas, without regard to the principles of conflicts of law
thereof. The parties hereto hereby agree and consent to be subject to the
exclusive jurisdiction of the United States District Court for the Southern
District of New York in any suit, action or proceeding seeking to enforce any
provision of, or based on any matter arising out of or in connection with, this
Agreement or the Transactions. Each party hereto hereby irrevocably waives, to
the fullest extent permitted by law, (i) any objection that it may now or
hereafter have to laying venue of any suit, action or proceeding brought in such
courts, and (ii) any claim that any suit, action or proceeding brought in such
courts has been brought in an inconvenient forum.
Section 8.6. DESCRIPTIVE HEADINGS. The descriptive headings herein
are inserted for convenience of reference only and are not intended to be part
of or to affect the meaning or interpretation of this Agreement.
-46-
<PAGE>
Section 8.7. PARTIES IN INTEREST. This Agreement shall be binding
upon and inure solely to the benefit of each party hereto and its successors and
permitted assigns, and except as provided in Sections 5.8 and 7.3 nothing in
this Agreement, express or implied, is intended to or shall confer upon any
other Person any rights, benefits or remedies of any nature whatsoever under or
by reason of this Agreement.
Section 8.8. COUNTERPARTS. This Agreement may be executed in two or
more counterparts, each of which shall be deemed to be an original, but all of
which shall constitute one and the same agreement.
-47-
<PAGE>
IN WITNESS WHEREOF, each of the parties hereto has caused this
Agreement to be duly executed on its behalf as of the day and year first above
written.
FOX PAINE MEDIC ACQUISITION CORPORATION
By: /s/ SAUL A. FOX
------------------------------------
Name: Saul A. Fox
Title: Chief Executive Officer
MAXXIM MEDICAL, INC.
By: /s/ KENNETH W. DAVIDSON
------------------------------------
Name: Kenneth W. Davidson
Title: Chairman, President and Chief
Executive Officer
By: /s/ DONALD R. DEPRIEST
------------------------------------
Name: Donald R. DePriest
Title: Director
[SIGNATURE PAGE TO MERGER AGREEMENT]
EXHIBIT 4.1
AMENDMENT NO. 1 TO RIGHTS AGREEMENT
Amendment No. 1 to the Rights Agreement, dated as of June 13, 1999, by
and between Maxxim Medical, Inc., a Texas corporation (the "Company"), and
Harris Trust and Savings Bank, an Illinois banking corporation (the "Rights
Agent"), at the Company's direction.
W I T N E S S E T H :
WHEREAS, on July 10, 1997 the Company and the Rights Agent entered into
a Rights Agreement (the "Agreement"), the terms of which are incorporated herein
by reference and made a part hereof;
WHEREAS, on June 13, 1999, the Board of Directors of the Company
determined to amend the Agreement and directed the Rights Agents to enter this
Amendment.
NOW, THEREFORE, in consideration of the premises and mutual agreements
herein set forth, and intending to be legally bound hereby, the parties hereto
agree that the Agreement shall be and hereby is amended in the following manner:
Section 1. AMENDMENT OF "CERTAIN DEFINITIONS".
(a) Section 1(j) of the Agreement is amended by deleting such section
in its entirety.
(b) Section 1(m) is hereby amended by deleting in its entirety the
first parenthetical clause therein which reads "(or such later date as may be
determined by action of a majority of Continuing Directors then in office)" and
by replacing all other references therein to the clause "Continuing Directors"
by the clause "members of the Board of Directors of the Company".
(c) Section 1(u) is hereby amended to read in its entirety as follows:
"Permitted Offer" shall mean a tender offer for all outstanding Common
Shares made in the manner prescribed by Section 14(d) of the Exchange
Act and the rules and regulations promulgated thereunder; PROVIDED,
HOWEVER, that members of the Board of Directors then in office have
unanimously determined that the offer is both adequate and otherwise in
the best interests of the Company and its shareholders (taking into
account all factors that the members of the Board of Directors deem
relevant).
Section 2. AMENDMENT OF "ISSUANCE OF RIGHTS CERTIFICATES". Section 3(a)
of the Agreement is hereby amended to add the following paragraph at the end
thereof:
"Notwithstanding any other provision of this Agreement, the occurrence
of (A) the approval, execution and delivery of the Agreement and Plan
of Merger, dated as of June 13, 1999 (as it may be amended from time to
time, the "Merger
<PAGE>
Agreement"), by and between Fox Paine Medic Acquisition Corporation, a
Texas corporation("FP Acquisition") which is affiliated with Fox Paine
& Company, LLC ("Fox Paine"), and the Company, and the Voting
Agreements by and between FP Acquisition and certain officers and
directors of the Company (as such agreements may be amended from time
to time, the "Voting Agreements"), (B) the consummation of the
transactions contemplated by the Merger Agreement or the Voting
Agreements or (C) the announcement of any of the foregoing events will
not, individually or collectively, cause (i) FP Acquisition, Fox Paine
and their Affiliates and Associates, either individually or as a group,
to be deemed an Acquiring Person, (ii) the Rights to become exercisable
or (iii) the occurrence of a Distribution Date, a Triggering Event or a
Shares Acquisition Date."
Section 3. AMENDMENT OF "REDEMPTION". Section 19(a) of the Agreement is
hereby amended to read in its entirety as follows:
"The Company may, at its option and with the approval of the Board of
Directors, at any time prior to the Close of Business on the earlier of
(i) the tenth day following the Shares Acquisition Date or such later
date as may be determined by unanimous action of the members of the
Board of Directors then in office and publicly announced by the Company
and (ii) the Final Expiration Date, redeem all but not less than all
the then outstanding Rights at a redemption price of $0.01 per Right,
appropriately adjusted to reflect any stock split, stock dividend or
similar transaction occurring after the date hereof (such redemption
price being herein referred to as the "Redemption Price") and the
Company may, at its option, pay the Redemption Price either in Common
Shares (based on the Current Per Share Market Price thereof at the time
of redemption) or cash. Such redemption of the Rights by the Company
may be made effective at such time, on such basis and with such
conditions as the Board of Directors in its sole discretion may
establish; PROVIDED, HOWEVER, if the Board of Directors of the Company
authorizes redemption of the Rights on or after the time a Person
becomes an Acquiring Person, then such authorization shall require the
unanimous concurrence of the members of the Board of Directors then in
office. The date on which the Board of Directors elects to make the
redemption effective shall be referred to as the "Redemption Date."
Section 4. AMENDMENT OF "EXCHANGE". Section 20(a) of the Agreement is
hereby amended by replacing the clause "by majority vote of the Board of
Directors and a majority vote of the Continuing Directors" with the clause "by
unanimous vote of the Board of Directors".
Section 5. AMENDMENT OF "SUPPLEMENTS AND AMENDMENTS". Section 23 of the
Agreement is hereby amended by replacing clause (iii) therein in its entirety to
read as follows:
"(iii) shorten or lengthen any time period hereunder (which shortening
or lengthening shall require the unanimous concurrence of the members
of the Board of Directors then in office)"
-2-
<PAGE>
Section 6. AMENDMENT OF "DETERMINATIONS AND ACTIONS BY THE BOARD OF
DIRECTORS, ETC.". Section 25 of the Agreement is hereby amended by deleting in
its entirety the parenthetical clause "(or, where specifically provided for
herein, the Continuing Directors)" and the clause "or the Continuing Directors"
wherever such clauses appear in such Section 25.
Section 7. RIGHTS AGREEMENT AS AMENDED. The term "Agreement" as used in
the Agreement shall be deemed to refer to the Agreement as amended hereby and
shall be effective as of the date hereof. It is expressly understood and agreed
that except as provided above, all terms, conditions and provisions contained in
the Agreement shall remain in full force and effect without any further change
or modification whatsoever.
IN WITNESS WHEREOF, the parties have caused this Amendment No. 1 to be
duly executed and their respective corporate seals to be hereunto affixed and
attested, all as of the day and year first above written.
Attest: MAXXIM MEDICAL, INC.
By: /s/ DONALD R. DEPRIEST By: /s/ KENNETH W. DAVIDSON
---------------------------- ------------------------
Name: Donald R. DePriest Name: Kenneth W. Davidson
Title: Director Title: Chairman, President and
Chief Executive Officer
Attest: HARRIS TRUST AND SAVINGS BANK,
as Rights Agent
By: /s/ BERNETTA YOUNG-GRAY By: /s/ LORRAINE RODEWALD
--------------------------- ------------------------
Name: Bernetta Young-Gray Name: Lorraine Rodewald
Title: Trust Officer Title: Vice President
-3-
EXHIBIT 99.1
MAXXIM MANAGEMENT TEAM TO ACQUIRE
MAXXIM MEDICAL FOR $26 PER SHARE IN CASH
FOX PAINE TO PROVIDE THE EQUITY FINANCING
TRANSACTION VALUED AT APPROXIMATELY $800 MILLION
For immediate release
Clearwater, FL and San Francisco, CA (June 14, 1999) Maxxim Medical,
Inc. (NYSE - MAM) announced today that a management group, led by Kenneth W.
Davidson, the Company's Chairman, Chief Executive Officer and President, with
equity financing provided by investment funds managed by Fox Paine & Company,
LLC, have entered into a definitive merger agreement to acquire the Company in a
recapitalization transaction. Under the terms of the merger agreement, holders
of all of the outstanding shares of Maxxim, except senior executive officers and
certain other current shareholders of Maxxim ("Rollover Shareholders"), will
receive $26.00 per share in cash. Based upon Maxxim Medical's closing price of
$19.875 on Friday, June 11, 1999, this represents a premium of 30.8%. In
connection with the merger, the existing debt of the Company will be refinanced,
with the Company making a consent solicitation and tender offer for all of its
outstanding 10 1/2% Senior Subordinated Notes, due 2006.
Kenneth W. Davidson, Chairman, President and Chief Executive Officer of
the Company stated, "We are pleased to have found a financial partner in Fox
Paine which is equally committed to our long-stated goal of being a leading
developer, manufacturer and distributor of a diversified range of single-use
medical specialty products."
Saul Fox, Chairman and Chief Executive Officer of Fox Paine said, "We
are delighted to be working with Ken Davidson, his energetic management team and
the over 5,000 talented Maxxim Medical employees to support their initiatives."
"Investing in medical products companies will continue to be an important focus
for our firm," added Dexter Paine, President of Fox Paine.
The proposed transaction is subject to certain conditions, including
shareholder approval, regulatory approvals, the availability of funding under
the existing equity and debt financing commitments and other customary closing
conditions. The merger has a total value in excess of $800 million, including
equity and debt. The transactions will be funded by equity and debt commitments
from Fox Paine and a debt commitment from The Chase Manhattan Corporation
providing the balance of the financing necessary to complete the transactions.
The commitments are subject to customary closing conditions.
Lazard Freres & Co. LLC acted as financial advisor to the Special
Committee of the Board of Directors of Maxxim Medical, which negotiated the
transaction. Chase Securities Inc. acted as financial advisor to Fox Paine.
The Rollover Shareholders, who will continue as shareholders of the
Company, have entered into voting agreements with the acquiror pursuant to which
they have agreed to vote all of their shares, representing approximately 8.0% of
Maxxim's outstanding common stock, in favor of the
<PAGE>
merger. The Company will call a special meeting of its shareholders as soon as
practicable to consider the approval of the merger.
Maxxim Medical, Inc. is a major, diversified developer, manufacturer
and marketer of specialty medical products for use in acute and alternate care
settings such as custom procedure trays, medical gloves, endoscopic and
laproscopic systems as well as electrosurgical and video systems for general
surgery, urology, gynecology, interventional radiology and critical care.
Fox Paine manages investment funds in excess of $500 million providing
equity capital to growth-oriented management-led buyouts and company expansion
programs. Fox Paine engages exclusively in friendly transactions developed in
cooperation with a company's management, shareholders and board of directors.
The Fox Paine funds' participants include the long-term equity arms of leading
domestic and international public and corporate pension funds, endowments and
financial institutions.
Certain statements in this release are "forward-looking statements"
within the meaning of the Private Litigation Reform Act of 1995. All
forward-looking statements involve risks and uncertainties. In particular, any
statements contained herein regarding the consummation and benefits of future
acquisitions, as well as expectations with respect to future sales, operating
efficiencies and product expansion, are subject to known and unknown risks,
uncertainties and contingencies, many of which are beyond the control of the
Company, which may cause actual results, performance or achievements to differ
materially from anticipated results, performance or achievements. Factors, that
might affect such forward-looking statements include, among other things,
overall economic and business conditions, the demand for the Company's goods and
services, competitive factors in the industries in which the Company competes,
changes in government regulation and the timing, impact and other uncertainties
of future acquisitions.
Contacts:
Maxxim Medical, Inc. Fox Paine & Company, LLC
Mary Lugris c/o Abernathy, MacGregor & Frank
727-561-2100 Andrew Brimmer
Loren Iati
Katherine Mittelbusher (212) 371-5999
Morgen Walke
(212) 850-5600
